dextromethorphan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
opioid receptor antagonists/agonists, morphinan derivates 842 125-71-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dextromethorphan HBr
  • dextromethorphan hydrochloride
  • dextromethorphan hydrobromide hydrate
  • dextromethorphan
  • (+)-Dextromethorphan
  • d-Methorphan
  • dextromethorphan hydrobromide
  • dextromethorphan hydriodide
  • dextromethorphan hydrobromide monohydrate
  • dextromethorphan polistirex
Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.
  • Molecular weight: 271.40
  • Formula: C18H25NO
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -4.50
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O
90 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 15 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.19 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.88 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 11 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 0.24 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,ZAP70 39
kinase-selectivity-class AXL,EIF2AK3,PDK4 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1957 FDA ANI PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 4541.76 9.87 8825 815281 279021 89525320
Completed suicide 3093.48 9.87 5077 819029 139981 89664360
Exposure to toxic agent 1919.20 9.87 1083 823023 6884 89797457
Intentional overdose 1653.25 9.87 3020 821086 90814 89713527
Acute hepatic failure 1151.95 9.87 1215 822891 21346 89782995
Overdose 1023.06 9.87 3459 820647 154250 89650091
Hepatic cytolysis 743.16 9.87 1144 822962 29772 89774569
Infusion related reaction 730.62 9.87 6368 817738 410412 89393929
Suicide attempt 688.76 9.87 1866 822240 73533 89730808
Injection site pain 629.60 9.87 401 823705 173298 89631043
Metabolic acidosis 553.34 9.87 1422 822684 54254 89750087
Intentional product misuse 526.74 9.87 1903 822203 87701 89716640
Poisoning deliberate 498.28 9.87 680 823426 15806 89788535
Product dose omission issue 475.35 9.87 1234 822872 290453 89513888
Folliculitis 440.94 9.87 3276 820830 201077 89603264
Sinusitis 438.02 9.87 4909 819197 338179 89466162
Drug ineffective 437.02 9.87 9441 814665 1374857 88429484
Lower respiratory tract infection 426.09 9.87 3806 820300 246853 89557488
Blood pressure fluctuation 415.94 9.87 1233 822873 51180 89753161
Analgesic drug level increased 406.27 9.87 280 823826 2639 89801702
Muscle injury 389.62 9.87 2847 821259 173807 89630534
Irritable bowel syndrome 360.25 9.87 3165 820941 204283 89600058
Injection site erythema 349.22 9.87 233 823873 98269 89706072
Duodenal ulcer perforation 342.22 9.87 3293 820813 217995 89586346
Helicobacter infection 332.39 9.87 3338 820768 223512 89580829
Ill-defined disorder 330.45 9.87 2839 821267 182052 89622289
Blister 321.74 9.87 3641 820465 251357 89552984
Sleep disorder due to general medical condition, insomnia type 319.49 9.87 2135 821971 126559 89677782
Rheumatoid arthritis 318.70 9.87 4846 819260 357768 89446573
Device expulsion 305.53 9.87 16 824090 40870 89763471
Impaired healing 293.60 9.87 3340 820766 230859 89573482
Hepatic enzyme increased 292.37 9.87 4756 819350 355980 89448361
Pericarditis 287.89 9.87 3736 820370 266415 89537926
Diarrhoea 286.05 9.87 6437 817669 932753 88871588
Suspected suicide attempt 285.62 9.87 147 823959 754 89803587
Suspected suicide 277.64 9.87 387 823719 9181 89795160
Anti-cyclic citrullinated peptide antibody positive 276.89 9.87 3328 820778 233105 89571236
Nasopharyngitis 248.50 9.87 5135 818971 401969 89402372
Medication error 245.90 9.87 1462 822644 83190 89721151
Depressed level of consciousness 243.78 9.87 1306 822800 71478 89732863
Disease progression 243.28 9.87 678 823428 155937 89648404
Wrong technique in product usage process 240.89 9.87 179 823927 71392 89732949
Throat irritation 232.84 9.87 969 823137 47726 89756615
Pyroglutamic acidosis 232.39 9.87 145 823961 1135 89803206
Anion gap 226.81 9.87 137 823969 1005 89803336
Gastrointestinal disorder 223.60 9.87 3426 820680 253261 89551080
Myelosuppression 219.70 9.87 106 824000 53485 89750856
Anaemia 218.57 9.87 2101 822005 350701 89453640
Hypersensitivity 210.15 9.87 5517 818589 449160 89355181
Injection site pruritus 206.59 9.87 116 823990 53718 89750623
Joint swelling 201.83 9.87 5997 818109 497303 89307038
Malignant neoplasm progression 193.83 9.87 427 823679 106443 89697898
Hand deformity 188.90 9.87 3763 820343 292599 89511742
Intentional product use issue 184.69 9.87 2884 821222 214008 89590333
Injection site swelling 182.33 9.87 165 823941 59674 89744667
Liver injury 181.61 9.87 2359 821747 168208 89636133
Stomatitis 181.49 9.87 3507 820599 271191 89533150
Injection site bruising 181.01 9.87 127 823979 52180 89752161
Hepatotoxicity 180.51 9.87 861 823245 44981 89759360
Synovitis 179.52 9.87 4092 820014 325660 89478681
White blood cell count decreased 170.85 9.87 859 823247 166250 89638091
Confusional state 170.84 9.87 4660 819446 381545 89422796
Cardiac failure congestive 170.35 9.87 405 823701 98289 89706052
Neutropenia 166.61 9.87 1278 822828 223626 89580715
Coagulopathy 165.29 9.87 527 823579 22762 89781579
Therapy interrupted 162.67 9.87 130 823976 49978 89754363
Discomfort 157.04 9.87 3429 820677 270906 89533435
Body temperature increased 155.00 9.87 810 823296 43900 89760441
Ear pruritus 154.09 9.87 245 823861 6558 89797783
Drug abuse 152.03 9.87 1274 822832 81073 89723268
Neuropathy peripheral 151.75 9.87 684 823422 136286 89668055
Blood pressure systolic abnormal 146.76 9.87 450 823656 19028 89785313
Wound 146.12 9.87 3698 820408 299282 89505059
Dry skin 143.73 9.87 372 823734 87701 89716640
Rheumatic fever 141.91 9.87 2066 822040 151055 89653286
Feeling abnormal 140.09 9.87 917 823189 166318 89638023
Therapy cessation 134.34 9.87 82 824024 36279 89768062
Myocardial infarction 132.45 9.87 505 823601 105467 89698874
Cardio-respiratory arrest 131.92 9.87 1005 823101 62135 89742206
Weight increased 130.47 9.87 4836 819270 413091 89391250
Blood pressure diastolic abnormal 127.77 9.87 435 823671 19446 89784895
Therapeutic product effect decreased 125.99 9.87 3361 820745 274210 89530131
Neoplasm progression 123.62 9.87 133 823973 44353 89759988
Prothrombin time ratio decreased 123.52 9.87 89 824017 906 89803435
Swelling 120.81 9.87 4807 819299 414251 89390090
Surgery 119.48 9.87 139 823967 44748 89759593
Hospitalisation 117.90 9.87 682 823424 127418 89676923
Coma 116.66 9.87 1090 823016 71542 89732799
Cardiac failure 115.84 9.87 556 823550 108940 89695401
Device dislocation 114.92 9.87 72 824034 31410 89772931
Poisoning 114.13 9.87 351 823755 14866 89789475
Blood pressure diastolic decreased 112.33 9.87 513 823593 26313 89778028
Sedation complication 110.89 9.87 373 823733 16571 89787770
Blood pressure systolic increased 110.54 9.87 908 823198 57437 89746904
Abortion spontaneous 109.96 9.87 202 823904 53854 89750487
Cytokine release syndrome 109.84 9.87 525 823581 27448 89776893
Muscle spasticity 109.67 9.87 621 823485 34701 89769640
Renal impairment 109.38 9.87 539 823567 104882 89699459
Hepatic failure 108.28 9.87 675 823431 39053 89765288
Pancytopenia 108.17 9.87 645 823461 119618 89684723
Osteonecrosis of jaw 107.45 9.87 118 823988 38985 89765356
Unevaluable event 106.29 9.87 211 823895 54637 89749704
Heart rate decreased 105.33 9.87 840 823266 52665 89751676
Drug resistance 102.65 9.87 76 824030 30373 89773968
Psoriasis 100.91 9.87 858 823248 146896 89657445
Rheumatoid factor positive 100.54 9.87 2153 821953 169497 89634844
Respiratory arrest 100.38 9.87 581 823525 32730 89771611
Creatinine renal clearance decreased 99.04 9.87 387 823719 18512 89785829
Injection site warmth 97.78 9.87 20 824086 17495 89786846
Glossodynia 97.59 9.87 3712 820394 318067 89486274
Injury 97.51 9.87 2417 821689 194932 89609409
Mobility decreased 96.32 9.87 2973 821133 247761 89556580
Diabetes mellitus 95.47 9.87 288 823818 64587 89739754
Bone pain 94.97 9.87 270 823836 61713 89742628
Seizure 94.77 9.87 908 823198 151721 89652620
Device malfunction 94.74 9.87 36 824070 20941 89783400
Accidental overdose 93.74 9.87 506 823600 27767 89776574
Injection site urticaria 93.70 9.87 24 824082 17987 89786354
Dehydration 93.40 9.87 1226 822880 193221 89611120
Injection site rash 92.87 9.87 52 824054 24121 89780220
Infection 92.16 9.87 4100 820006 357994 89446347
Device difficult to use 91.85 9.87 23 824083 17502 89786839
Product substitution issue 91.78 9.87 25 824081 17983 89786358
Product storage error 90.97 9.87 35 824071 20206 89784135
Myalgia 90.53 9.87 1087 823019 174038 89630303
Injection site haemorrhage 90.01 9.87 75 824031 28243 89776098
Dermatitis atopic 89.45 9.87 51 824055 23421 89780920
Swollen joint count increased 89.05 9.87 1464 822642 109742 89694599
Red blood cell sedimentation rate abnormal 88.84 9.87 55 824051 24149 89780192
Nausea 87.51 9.87 8804 815302 1101512 88702829
Platelet count decreased 86.67 9.87 811 823295 136158 89668183
Infusion site swelling 85.73 9.87 268 823838 11452 89792889
Vision blurred 85.30 9.87 619 823487 109674 89694667
Respiratory depression 84.12 9.87 322 823784 15253 89789088
Renal failure 83.20 9.87 775 823331 130232 89674109
Device issue 82.41 9.87 88 824018 29449 89774892
Oxygen saturation decreased 82.03 9.87 1404 822702 106079 89698262
Cerebrovascular accident 80.52 9.87 726 823380 122807 89681534
Infusion site pruritus 80.22 9.87 185 823921 6580 89797761
Type 2 diabetes mellitus 80.20 9.87 2418 821688 200826 89603515
Infusion site pain 79.36 9.87 373 823733 19365 89784976
Schizoaffective disorder 77.42 9.87 155 823951 4992 89799349
Contusion 77.32 9.87 2903 821203 248313 89556028
Pemphigus 77.08 9.87 3673 820433 323191 89481150
Dyspnoea exertional 76.49 9.87 367 823739 71921 89732420
Acute lung injury 75.25 9.87 80 824026 1418 89802923
Injection site mass 74.64 9.87 55 824051 22035 89782306
Dizziness 74.63 9.87 4492 819614 584792 89219549
Accidental exposure to product 74.57 9.87 172 823934 42194 89762147
Visual acuity reduced 74.41 9.87 62 824044 23348 89780993
Full blood count abnormal 74.22 9.87 137 823969 36460 89767881
Infusion site erythema 74.15 9.87 283 823823 13387 89790954
Breast cancer 73.96 9.87 246 823860 53515 89750826
Pyroglutamate increased 73.94 9.87 44 824062 313 89804028
Leukopenia 73.71 9.87 574 823532 100136 89704205
Therapeutic product effect incomplete 73.70 9.87 1279 822827 192617 89611724
Bone marrow failure 73.31 9.87 112 823994 32109 89772232
Blood cholesterol increased 73.23 9.87 2441 821665 205571 89598770
Peripheral swelling 73.17 9.87 4520 819586 408586 89395755
Hepatic necrosis 73.00 9.87 173 823933 6265 89798076
Injection site reaction 72.56 9.87 514 823592 91566 89712775
Arthropathy 71.84 9.87 4044 820062 362198 89442143
Palmar-plantar erythrodysaesthesia syndrome 71.17 9.87 90 824016 27933 89776408
Pharyngeal paraesthesia 70.10 9.87 113 823993 3061 89801280
Multiple sclerosis relapse 69.47 9.87 243 823863 52062 89752279
Blood glucose increased 68.71 9.87 545 823561 94701 89709640
Transient ischaemic attack 68.43 9.87 185 823921 42991 89761350
Night sweats 68.10 9.87 1592 822514 127174 89677167
Posterior reversible encephalopathy syndrome 67.57 9.87 62 824044 22277 89782064
Blood calcium decreased 67.34 9.87 488 823618 29694 89774647
Ear pain 67.33 9.87 812 823294 56890 89747451
Respiratory failure 67.08 9.87 720 823386 117698 89686643
Sopor 65.93 9.87 76 824030 24568 89779773
Drug-induced liver injury 65.76 9.87 1171 822935 89147 89715194
Atrial fibrillation 65.40 9.87 839 823267 132772 89671569
Exposure via ingestion 64.51 9.87 99 824007 2568 89801773
Gastrointestinal haemorrhage 63.44 9.87 520 823586 89728 89714613
Drug use disorder 63.08 9.87 193 823913 8150 89796191
Hepatitis acute 62.89 9.87 230 823876 10657 89793684
Metastases to bone 62.63 9.87 84 824022 25421 89778920
Suicidal ideation 62.30 9.87 404 823702 73451 89730890
Full blood count decreased 62.13 9.87 109 823997 29580 89774761
Pyrexia 62.01 9.87 6886 817220 653599 89150742
Blood pressure increased 61.38 9.87 2282 821824 194935 89609406
Loss of consciousness 61.33 9.87 901 823205 139337 89665004
Metastases to liver 60.97 9.87 105 824001 28702 89775639
Hypocoagulable state 60.95 9.87 74 824032 1525 89802816
Urinary tract infection 60.88 9.87 2219 821887 303413 89500928
Drug dose omission by device 60.73 9.87 10 824096 10221 89794120
Thrombosis 60.13 9.87 404 823702 72847 89731494
Facet joint syndrome 59.82 9.87 1241 822865 97148 89707193
Pulmonary hypertension 59.58 9.87 193 823913 42330 89762011
Epistaxis 58.70 9.87 493 823613 84632 89719709
Breast cancer female 58.68 9.87 31 824075 14855 89789486
No adverse event 57.79 9.87 371 823735 67611 89736730
Myelodysplastic syndrome 57.52 9.87 63 824043 20840 89783501
Hypomania 57.46 9.87 195 823911 8702 89795639
Fall 57.25 9.87 3694 820412 478116 89326225
Schizophrenia 57.17 9.87 278 823828 14636 89789705
Sepsis 57.05 9.87 1223 822883 178591 89625750
Therapeutic response unexpected 56.90 9.87 69 824037 21811 89782530
Hypocalcaemia 56.83 9.87 196 823910 42172 89762169
Interstitial lung disease 56.60 9.87 434 823672 75971 89728370
Systemic lupus erythematosus 56.54 9.87 3918 820188 357978 89446363
Hypothyroidism 56.04 9.87 270 823836 52857 89751484
Haematotoxicity 55.80 9.87 22 824084 12513 89791828
Syncope 55.72 9.87 859 823247 131804 89672537
Coronary artery disease 55.63 9.87 141 823965 33482 89770859
Cognitive disorder 55.28 9.87 913 823193 68494 89735847
Drug level increased 55.26 9.87 437 823669 27325 89777016
Hepatitis fulminant 54.85 9.87 115 823991 3830 89800511
Anion gap abnormal 54.54 9.87 37 824069 339 89804002
Tremor 54.53 9.87 1022 823084 152151 89652190
Basal cell carcinoma 54.48 9.87 141 823965 33248 89771093
Hypokalaemia 54.38 9.87 851 823255 130265 89674076
Prothrombin time shortened 54.32 9.87 84 824022 2194 89802147
Bursitis 54.00 9.87 1574 822532 130080 89674261
Infusion site extravasation 53.72 9.87 211 823895 10117 89794224
Injection site induration 52.48 9.87 15 824091 10453 89793888
Lip dry 52.41 9.87 1245 822861 99710 89704631
Thrombotic microangiopathy 52.16 9.87 40 824066 15703 89788638
Haemorrhage 51.87 9.87 393 823713 68976 89735365
Blood potassium decreased 51.84 9.87 240 823866 47487 89756854
Depression 51.51 9.87 2221 821885 298380 89505961
Jaundice cholestatic 51.29 9.87 204 823902 9839 89794502
Deep vein thrombosis 51.11 9.87 559 823547 91061 89713280
Spinal stenosis 50.78 9.87 50 824056 17374 89786967
Mucosal inflammation 50.78 9.87 311 823795 57314 89747027
Complication of device insertion 50.42 9.87 16 824090 10420 89793921
Drug withdrawal syndrome 50.24 9.87 117 823989 28606 89775735
Hepatic encephalopathy 50.16 9.87 253 823853 13519 89790822
Osteonecrosis 49.94 9.87 102 824004 26139 89778202
Drug hypersensitivity 49.16 9.87 3590 820516 460019 89344322
Cardiac disorder 49.04 9.87 309 823797 56563 89747778
Brain oedema 49.02 9.87 298 823808 17087 89787254
Electric shock 48.99 9.87 69 824037 1653 89802688
Vaginal haemorrhage 48.80 9.87 135 823971 31136 89773205
Disease recurrence 48.62 9.87 177 823929 37476 89766865
Ductus arteriosus premature closure 48.28 9.87 36 824070 388 89803953
Diabetic ketoacidosis 47.19 9.87 94 824012 24313 89780028
Heart rate increased 46.90 9.87 1352 822754 111550 89692791
Hyperkalaemia 46.72 9.87 372 823734 64592 89739749
Fibromyalgia 46.71 9.87 2309 821797 203960 89600381
Metastases to lung 46.47 9.87 46 824060 15945 89788396
Carpal tunnel syndrome 46.40 9.87 92 824014 23836 89780505
Hyperlipidaemia 46.28 9.87 86 824020 22830 89781511
Pathogen resistance 45.86 9.87 9 824097 8106 89796235
Orthostatic hypotension 45.52 9.87 581 823525 41246 89763095
Post transplant lymphoproliferative disorder 45.51 9.87 5 824101 6944 89797397
Transplant rejection 45.44 9.87 30 824076 12728 89791613
Multiple-drug resistance 45.28 9.87 8 824098 7768 89796573
Joint range of motion decreased 45.00 9.87 1581 822525 134062 89670279
Product dose omission in error 45.00 9.87 73 824033 20430 89783911
Contraindicated product administered 44.71 9.87 3435 820671 316704 89487637
Genital haemorrhage 44.50 9.87 12 824094 8690 89795651
Skin exfoliation 44.30 9.87 399 823707 67514 89736827
Chronic kidney disease 44.16 9.87 271 823835 49920 89754421
Pain in extremity 44.08 9.87 3512 820594 447017 89357324
Decreased appetite 43.99 9.87 2891 821215 373649 89430692
Neurotoxicity 43.85 9.87 80 824026 21387 89782954
Injection site discolouration 43.78 9.87 15 824091 9305 89795036
Eczema 43.69 9.87 291 823815 52579 89751762
Hyponatraemia 43.30 9.87 905 823201 132633 89671708
Impaired quality of life 43.17 9.87 91 824015 23053 89781288
Poor venous access 43.15 9.87 315 823791 19212 89785129
Polyneuropathy 42.32 9.87 69 824037 19272 89785069
Complication of device removal 42.26 9.87 4 824102 6251 89798090
Muscle spasms 42.12 9.87 1866 822240 250017 89554324
Pulmonary embolism 42.00 9.87 888 823218 129932 89674409
Renal disorder 41.94 9.87 189 823917 37670 89766671
Premature delivery 41.46 9.87 196 823910 38566 89765775
Skin burning sensation 41.03 9.87 72 824034 19539 89784802
Device use error 40.82 9.87 8 824098 7213 89797128
Plasma cell myeloma 40.49 9.87 212 823894 40616 89763725
Urticaria 40.48 9.87 3336 820770 309398 89494943
Neutrophil count decreased 40.47 9.87 435 823671 71097 89733244
Heart rate irregular 40.37 9.87 367 823739 23901 89780440
Pneumocystis jirovecii pneumonia 40.31 9.87 85 824021 21531 89782810
Septic shock 40.25 9.87 531 823575 83629 89720712
Respiratory disorder 40.20 9.87 820 823286 63996 89740345
Device breakage 40.13 9.87 41 824065 14003 89790338
Clostridium test positive 39.96 9.87 124 823982 5277 89799064
Cerebral infarction 39.90 9.87 117 823989 26479 89777862
Product preparation error 39.52 9.87 22 824084 10239 89794102
Cellulitis 39.51 9.87 588 823518 90749 89713592
Product prescribing error 39.39 9.87 141 823965 30004 89774337
Rash pruritic 38.85 9.87 520 823586 81694 89722647
Ascites 38.33 9.87 265 823841 47475 89756866
Deep vein thrombosis postoperative 38.21 9.87 878 823228 69931 89734410
Femur fracture 37.89 9.87 254 823852 45828 89758513
Thrombocytopenia 37.88 9.87 1532 822574 207193 89597148
Skin ulcer 37.77 9.87 283 823823 49792 89754549
Skin discolouration 37.58 9.87 242 823864 44073 89760268
Second primary malignancy 37.51 9.87 24 824082 10354 89793987
Dry eye 37.50 9.87 341 823765 57590 89746751
Hypercalcaemia 37.29 9.87 172 823934 34068 89770273
Musculoskeletal disorder 37.02 9.87 90 824016 21679 89782662
Acute myeloid leukaemia 36.97 9.87 83 824023 20557 89783784
Blood pressure diastolic increased 36.88 9.87 222 823884 12684 89791657
Complication associated with device 36.67 9.87 76 824030 19373 89784968
Therapeutic response decreased 36.66 9.87 584 823522 89145 89715196
Hypertensive crisis 36.57 9.87 66 824040 17718 89786623
Dyskinesia 36.06 9.87 190 823916 36344 89767997
Tardive dyskinesia 35.92 9.87 28 824078 10902 89793439
Pulmonary arterial hypertension 35.90 9.87 120 823986 26067 89778274
Infusion site bruising 35.77 9.87 104 824002 4268 89800073
Haemoglobin decreased 35.66 9.87 1161 822945 160795 89643546
Crystal urine present 35.61 9.87 55 824051 1435 89802906
Dysgeusia 35.51 9.87 306 823800 52254 89752087
Irritability 35.46 9.87 185 823921 35477 89768864
Gait disturbance 35.17 9.87 1973 822133 258523 89545818
Cytomegalovirus infection 35.05 9.87 124 823982 26478 89777863
Amenorrhoea 34.90 9.87 33 824073 11689 89792652
Sleep apnoea syndrome 34.86 9.87 159 823947 31588 89772753
Hypothermia 34.85 9.87 252 823854 15323 89789018
Dissociation 34.83 9.87 9 824097 6706 89797635
Heavy menstrual bleeding 34.82 9.87 85 824021 20445 89783896
Drug tolerance 34.64 9.87 69 824037 17847 89786494
Hypomagnesaemia 34.62 9.87 186 823920 35402 89768939
Right ventricular failure 34.59 9.87 77 824029 19128 89785213
Anticipatory anxiety 34.48 9.87 49 824057 1184 89803157
Abnormal dreams 34.34 9.87 31 824075 11226 89793115
White blood cells urine positive 34.00 9.87 133 823973 6365 89797976
Coeliac disease 33.76 9.87 582 823524 44028 89760313
Anion gap increased 33.71 9.87 68 824038 2202 89802139
Treatment noncompliance 33.69 9.87 304 823802 51423 89752918
Staphylococcal infection 33.63 9.87 280 823826 48159 89756182
Neoplasm malignant 33.55 9.87 176 823930 33704 89770637
Cardiomyopathy 33.22 9.87 85 824021 20121 89784220
Toxicologic test abnormal 33.13 9.87 37 824069 695 89803646
Multiple drug therapy 33.12 9.87 139 823967 6870 89797471
Sensitivity to weather change 33.07 9.87 20 824086 8894 89795447
Cytopenia 33.06 9.87 68 824038 17381 89786960
Acute myocardial infarction 33.03 9.87 184 823922 34706 89769635
Ageusia 32.76 9.87 60 824046 16016 89788325
Body temperature decreased 32.69 9.87 346 823760 23470 89780871
Administration site swelling 32.60 9.87 53 824053 1446 89802895
Product complaint 32.60 9.87 45 824061 13455 89790886
Pleural effusion 32.30 9.87 773 823333 111218 89693123
Sleep disorder 32.12 9.87 2151 821955 195879 89608462
Skin necrosis 32.11 9.87 66 824040 16875 89787466
Application site pain 31.94 9.87 3 824103 4717 89799624
Thinking abnormal 31.58 9.87 36 824070 11696 89792645
Burning sensation 31.57 9.87 397 823709 63055 89741286
Ankylosing spondylitis 31.49 9.87 44 824062 13089 89791252
Hypercholesterolaemia 31.27 9.87 1167 822939 99725 89704616
Blood parathyroid hormone decreased 31.26 9.87 39 824067 12177 89792164
Pain in jaw 31.26 9.87 282 823824 47703 89756638
Incorrect dose administered by device 31.11 9.87 7 824099 5730 89798611
Autoimmune disorder 31.04 9.87 916 823190 75828 89728513
Dermatitis 31.02 9.87 101 824005 22119 89782222
Drug ineffective for unapproved indication 30.95 9.87 423 823683 66221 89738120
Inflammation 30.80 9.87 1950 822156 176642 89627699
Analgesic drug level above therapeutic 30.63 9.87 19 824087 147 89804194
Flatulence 30.62 9.87 235 823871 41132 89763209
Cardiac failure acute 30.62 9.87 38 824068 11891 89792450
Hyperglycaemia 30.45 9.87 306 823800 50664 89753677
Drug intolerance 30.38 9.87 4576 819530 443015 89361326
Weight fluctuation 30.03 9.87 293 823813 19456 89784885
Product use in unapproved indication 30.00 9.87 2640 821466 333596 89470745
Breast cancer stage I 29.96 9.87 26 824080 9598 89794743
Exposure via skin contact 29.75 9.87 32 824074 10673 89793668
Palpitations 29.66 9.87 982 823124 135746 89668595
Gastric disorder 29.50 9.87 180 823926 33204 89771137
Gestational diabetes 29.00 9.87 32 824074 10550 89793791
Ductus arteriosus stenosis foetal 28.97 9.87 21 824085 216 89804125
Urine abnormality 28.79 9.87 143 823963 7594 89796747
Urinary sediment present 28.64 9.87 62 824044 2112 89802229
Eye pruritus 28.63 9.87 151 823955 28876 89775465
Methaemoglobinaemia 28.62 9.87 91 824015 3924 89800417
Paraesthesia 28.52 9.87 1926 822180 248400 89555941
Unintended pregnancy 28.52 9.87 17 824089 7620 89796721
Infusion site rash 28.46 9.87 67 824039 2416 89801925
Product adhesion issue 28.44 9.87 6 824100 5136 89799205
Aspergillus infection 28.28 9.87 34 824072 10789 89793552
Embedded device 27.96 9.87 3 824103 4245 89800096
Uterine perforation 27.95 9.87 17 824089 7537 89796804
Osteomyelitis 27.94 9.87 144 823962 27702 89776639
Urine leukocyte esterase positive 27.75 9.87 79 824027 3203 89801138
Respiratory rate increased 27.65 9.87 244 823862 15757 89788584
Brain death 27.63 9.87 90 824016 3931 89800410
Therapy partial responder 27.56 9.87 105 824001 21938 89782403
Cerebral haemorrhage 27.53 9.87 192 823914 34330 89770011
Disturbance in social behaviour 27.46 9.87 3 824103 4185 89800156
Intermenstrual bleeding 27.42 9.87 26 824080 9197 89795144
Pelvic pain 27.31 9.87 62 824044 15295 89789046
Fixed eruption 27.11 9.87 53 824053 1677 89802664
Specific gravity urine decreased 27.09 9.87 35 824071 770 89803571
Haemophagocytic lymphohistiocytosis 27.01 9.87 63 824043 15396 89788945
Cholestasis 26.90 9.87 472 823634 35827 89768514
Oral pruritus 26.89 9.87 73 824033 2878 89801463
Galactorrhoea 26.79 9.87 5 824101 4667 89799674
Rheumatoid lung 26.75 9.87 3 824103 4100 89800241
Eye irritation 26.60 9.87 190 823916 33788 89770553
Ovarian hyperstimulation syndrome 26.57 9.87 10 824096 5852 89798489
Angina unstable 26.54 9.87 16 824090 7127 89797214
Ventricular extrasystoles 26.51 9.87 50 824056 13200 89791141
Tinnitus 26.49 9.87 257 823849 42845 89761496
Extrapyramidal disorder 26.48 9.87 69 824037 16234 89788107
Mitral valve incompetence 26.44 9.87 110 823996 22414 89781927
Drug interaction 26.39 9.87 2159 821947 274294 89530047
Pruritus 26.28 9.87 5440 818666 536085 89268256
Food allergy 26.09 9.87 350 823756 25128 89779213
Foot operation 26.03 9.87 26 824080 8975 89795366
Medication overuse headache 26.01 9.87 48 824058 1453 89802888
Haematochezia 25.89 9.87 471 823635 70442 89733899
Oedema peripheral 25.89 9.87 2006 822100 255909 89548432
Pregnancy with contraceptive device 25.88 9.87 7 824099 5059 89799282
Abdominal pain upper 25.81 9.87 3428 820678 329246 89475095
Serotonin syndrome 25.75 9.87 486 823620 37401 89766940
Systemic infection 25.55 9.87 6 824100 4769 89799572
Dysphoria 25.48 9.87 12 824094 6142 89798199
Speech disorder 25.47 9.87 278 823828 45307 89759034
Low turnover osteopathy 25.31 9.87 4 824102 4214 89800127
Mood altered 25.30 9.87 76 824030 17068 89787273
Enthesopathy 25.16 9.87 29 824077 9375 89794966
Injury associated with device 25.12 9.87 5 824101 4459 89799882
Peripheral venous disease 25.12 9.87 967 823139 82954 89721387
Wound infection 25.10 9.87 1196 822910 105206 89699135
Head injury 25.10 9.87 173 823933 31015 89773326
Limb discomfort 25.08 9.87 223 823883 37837 89766504
Polycystic ovaries 25.04 9.87 10 824096 5644 89798697
Vasoplegia syndrome 25.04 9.87 69 824037 2745 89801596
Disturbance in attention 24.86 9.87 291 823815 46818 89757523
Product label confusion 24.70 9.87 317 823789 22533 89781808
Chronic graft versus host disease 24.67 9.87 4 824102 4135 89800206
Device deployment issue 24.67 9.87 7 824099 4902 89799439
Weight decreased 24.65 9.87 3051 821055 376859 89427482
Pericardial effusion 24.63 9.87 215 823891 36618 89767723
Fracture 24.58 9.87 110 823996 21966 89782375
Cardiotoxicity 24.57 9.87 41 824065 11348 89792993
Dyspnoea 24.53 9.87 7395 816711 873560 88930781
Iron deficiency anaemia 24.52 9.87 121 823985 23541 89780800
Skin cancer 24.51 9.87 54 824052 13465 89790876
Sedation 24.37 9.87 592 823514 47579 89756762
Immune reconstitution inflammatory syndrome 24.34 9.87 17 824089 7002 89797339
Lactic acidosis 24.27 9.87 318 823788 50145 89754196
Renal failure neonatal 24.22 9.87 18 824088 193 89804148
Neutrophil percentage increased 24.15 9.87 71 824035 2932 89801409
Product quality issue 24.14 9.87 543 823563 78782 89725559
Skin irritation 24.12 9.87 55 824051 13548 89790793
Grip strength decreased 24.10 9.87 1051 823055 91525 89712816
Oral pain 24.04 9.87 186 823920 32497 89771844
Intentional dose omission 24.03 9.87 82 824024 17701 89786640
Paraesthesia ear 24.02 9.87 25 824081 432 89803909
Polyarthritis 23.86 9.87 86 824020 18264 89786077
X-ray abnormal 23.81 9.87 561 823545 44863 89759478
Infusion site haemorrhage 23.80 9.87 105 824001 5306 89799035
Alanine aminotransferase increased 23.79 9.87 1310 822796 117028 89687313
Skin lesion 23.73 9.87 221 823885 37144 89767197
Lymphadenopathy 23.68 9.87 284 823822 45491 89758850
Hypertransaminasaemia 23.68 9.87 234 823872 15591 89788750
Mixed liver injury 23.65 9.87 134 823972 7489 89796852
Osteopenia 23.62 9.87 118 823988 22884 89781457
Lymphoproliferative disorder 23.52 9.87 5 824101 4257 89800084
Hip fracture 23.51 9.87 190 823916 32887 89771454
Granuloma skin 23.46 9.87 38 824068 10642 89793699
Joint destruction 23.34 9.87 54 824052 13233 89791108
Arterial occlusive disease 23.19 9.87 193 823913 12253 89792088
Prescribed overdose 23.17 9.87 1098 823008 96527 89707814
Endophthalmitis 22.96 9.87 7 824099 4678 89799663
C-reactive protein 22.94 9.87 407 823699 30960 89773381
Infusion site mass 22.87 9.87 57 824049 2132 89802209
Withdrawal syndrome 22.87 9.87 116 823990 22408 89781933
Panniculitis 22.87 9.87 62 824044 14396 89789945
Cryopyrin associated periodic syndrome 22.82 9.87 27 824079 541 89803800
Blood immunoglobulin E increased 22.82 9.87 6 824100 4419 89799922
Shoulder arthroplasty 22.76 9.87 5 824101 4161 89800180
Hallucination, auditory 22.73 9.87 72 824034 15903 89788438
Incorrect drug administration rate 22.70 9.87 101 824005 5122 89799219
Neurologic neglect syndrome 22.67 9.87 148 823958 8699 89795642
Coagulation factor decreased 22.59 9.87 17 824089 186 89804155
Hypotension 22.56 9.87 3331 820775 322066 89482275
Bundle branch block left 22.55 9.87 23 824083 7862 89796479
Sciatica 22.54 9.87 1133 822973 100249 89704092
Lymphoma 22.48 9.87 57 824049 13534 89790807
Device leakage 22.47 9.87 35 824071 9956 89794385
Left ventricular dysfunction 22.39 9.87 64 824042 14605 89789736
Loss of personal independence in daily activities 22.38 9.87 1010 823096 135095 89669246
Device failure 22.25 9.87 18 824088 6879 89797462
Multiple organ dysfunction syndrome 22.18 9.87 463 823643 67873 89736468
Dysstasia 22.18 9.87 135 823971 24917 89779424
Product use issue 22.13 9.87 3371 820735 326548 89477793
Acute graft versus host disease 22.13 9.87 11 824095 5457 89798884
Haematuria 22.03 9.87 207 823899 34730 89769611
Visual impairment 22.02 9.87 981 823125 131384 89672957
Finger deformity 22.01 9.87 421 823685 32476 89771865
Product physical issue 22.00 9.87 12 824094 5648 89798693
Cardiovascular disorder 21.99 9.87 57 824049 13435 89790906
Musculoskeletal stiffness 21.94 9.87 3047 821059 293485 89510856
Nephrolithiasis 21.92 9.87 314 823792 48771 89755570
Vital capacity decreased 21.85 9.87 50 824056 1769 89802572
Intervertebral disc protrusion 21.81 9.87 151 823955 27045 89777296
Sputum culture positive 21.81 9.87 57 824049 2196 89802145
Hepatitis cholestatic 21.81 9.87 143 823963 8418 89795923
Tendonitis 21.74 9.87 110 823996 21262 89783079
Foetal exposure during pregnancy 21.71 9.87 268 823838 42707 89761634
Epstein-Barr virus infection 21.62 9.87 38 824068 10306 89794035
Gangrene 21.56 9.87 195 823911 12681 89791660
Low density lipoprotein increased 21.55 9.87 25 824081 8060 89796281
Renal papillary necrosis 21.50 9.87 19 824087 265 89804076
Generalised tonic-clonic seizure 21.50 9.87 208 823898 34695 89769646
Infective pulmonary exacerbation of cystic fibrosis 21.27 9.87 38 824068 10241 89794100
Skin disorder 21.25 9.87 222 823884 36484 89767857
Hepatitis B reactivation 21.25 9.87 5 824101 3969 89800372
Macular oedema 21.23 9.87 9 824097 4900 89799441
Groin pain 21.16 9.87 50 824056 12163 89792178
Personality disorder 21.11 9.87 189 823917 12255 89792086
Somnolence 21.09 9.87 2191 821915 206893 89597448
Physical deconditioning 21.09 9.87 56 824050 2179 89802162
Temperature regulation disorder 21.05 9.87 214 823892 14365 89789976
Invasive ductal breast carcinoma 21.03 9.87 24 824082 7794 89796547
Electrolyte imbalance 21.00 9.87 128 823978 23617 89780724
Delirium 20.93 9.87 1155 822951 103204 89701137
Acidosis 20.88 9.87 192 823914 12544 89791797
Hypertension 20.88 9.87 4583 819523 452949 89351392
Device related infection 20.77 9.87 143 823963 25643 89778698
Pre-existing condition improved 20.73 9.87 32 824074 9137 89795204
Blood creatine increased 20.65 9.87 121 823985 6846 89797495
Encephalopathy 20.63 9.87 561 823545 45883 89758458
Colorectal cancer 20.61 9.87 5 824101 3888 89800453
Lymphocyte percentage decreased 20.60 9.87 69 824037 3058 89801283
Mental disorder 20.58 9.87 191 823915 32127 89772214
Varicella zoster virus infection 20.49 9.87 5 824101 3872 89800469
Hyperprolactinaemia 20.42 9.87 12 824094 5421 89798920
Supraventricular tachycardia 20.30 9.87 78 824028 16258 89788083
Infusion site nodule 20.30 9.87 47 824059 1676 89802665
Skin toxicity 20.28 9.87 19 824087 6760 89797581
Pancreatic carcinoma 20.15 9.87 28 824078 8349 89795992
Ocular hyperaemia 20.15 9.87 203 823903 33595 89770746
Granuloma 20.13 9.87 16 824090 6169 89798172
Tricuspid valve incompetence 20.08 9.87 81 824025 16650 89787691
General physical health deterioration 20.07 9.87 3595 820511 351520 89452821
Mucormycosis 20.05 9.87 5 824101 3816 89800525
Rebound effect 20.05 9.87 34 824072 9350 89794991
International normalised ratio increased 20.03 9.87 568 823538 46748 89757593
Fear of injection 19.95 9.87 29 824077 8486 89795855
Glucose tolerance impaired 19.91 9.87 26 824080 7959 89796382
Eye haemorrhage 19.86 9.87 39 824067 10141 89794200
Rheumatoid nodule 19.83 9.87 105 824001 20061 89784280
Spinal osteoarthritis 19.79 9.87 98 824008 19050 89785291
C-reactive protein abnormal 19.75 9.87 1379 822727 126050 89678291
Diffuse large B-cell lymphoma recurrent 19.74 9.87 4 824102 3522 89800819
Oral discomfort 19.73 9.87 41 824065 10442 89793899
Thyroid neoplasm 19.72 9.87 6 824100 4015 89800326
Injection site nodule 19.67 9.87 8 824098 4465 89799876
Cytomegalovirus viraemia 19.64 9.87 24 824082 7562 89796779
Abortion induced 19.55 9.87 50 824056 11838 89792503
Bezoar 19.52 9.87 62 824044 2672 89801669
Intestinal haemorrhage 19.48 9.87 8 824098 4439 89799902
Product administration interrupted 19.44 9.87 54 824052 12438 89791903
Soft tissue disorder 19.44 9.87 84 824022 4206 89800135
Device defective 19.42 9.87 4 824102 3482 89800859
Gastritis 19.39 9.87 265 823841 41488 89762853
Postmortem blood drug level increased 19.39 9.87 28 824078 687 89803654
Intracranial pressure increased 19.36 9.87 117 823989 6694 89797647
Sleep disorder due to a general medical condition 19.35 9.87 288 823818 44450 89759891
Administration site pain 19.33 9.87 37 824069 1152 89803189
Congestive cardiomyopathy 19.33 9.87 23 824083 7331 89797010
Gastrointestinal pain 19.32 9.87 46 824060 11160 89793181
Asthma-chronic obstructive pulmonary disease overlap syndrome 19.27 9.87 92 824014 4807 89799534
Bone disorder 19.23 9.87 127 823979 22993 89781348
Osmolar gap 19.22 9.87 12 824094 94 89804247
Uterine leiomyoma 19.20 9.87 44 824062 10820 89793521
Blood pH decreased 19.18 9.87 59 824047 2499 89801842
Large intestine polyp 19.15 9.87 35 824071 9351 89794990
Mood swings 19.15 9.87 110 823996 20592 89783749
Arteriosclerosis 19.15 9.87 44 824062 10809 89793532
Central nervous system lesion 19.14 9.87 49 824057 11597 89792744
Personality change 19.13 9.87 23 824083 7298 89797043
Cystic fibrosis 19.11 9.87 6 824100 3935 89800406
Spinal operation 19.09 9.87 40 824066 10156 89794185
Brain stem glioma 19.08 9.87 15 824091 176 89804165
Acute respiratory failure 19.01 9.87 275 823831 42643 89761698
Needle issue 19.00 9.87 64 824042 13870 89790471
Drug eruption 18.96 9.87 218 823888 35189 89769152
Sexual dysfunction 18.94 9.87 10 824096 4794 89799547
Liver disorder 18.91 9.87 1313 822793 119956 89684385
Cytomegalovirus infection reactivation 18.84 9.87 26 824080 7774 89796567
Ventricular fibrillation 18.81 9.87 65 824041 13979 89790362
Incorrect dose administered 18.78 9.87 560 823546 78370 89725971
Mydriasis 18.73 9.87 214 823892 14798 89789543
Anger 18.72 9.87 63 824043 13657 89790684
Gastrointestinal toxicity 18.70 9.87 36 824070 9431 89794910
Herpes zoster 18.62 9.87 688 823418 93956 89710385
Hypervolaemia 18.61 9.87 199 823907 32558 89771783
Acute graft versus host disease in skin 18.61 9.87 10 824096 4746 89799595
Diplopia 18.59 9.87 169 823937 28545 89775796
Carotid artery thrombosis 18.58 9.87 144 823962 8948 89795393
Injection site discomfort 18.55 9.87 16 824090 5924 89798417
Mania 18.50 9.87 66 824040 14058 89790283
Specific gravity urine abnormal 18.40 9.87 11 824095 79 89804262
Thyroid cancer 18.35 9.87 18 824088 6266 89798075
Product residue present 18.34 9.87 8 824098 4283 89800058
Hiatus hernia 18.34 9.87 145 823961 25216 89779125
Adjustment disorder with depressed mood 18.20 9.87 659 823447 56094 89748247
Aortic valve incompetence 18.19 9.87 20 824086 6604 89797737
Aggression 18.13 9.87 155 823951 26513 89777828
Total lung capacity increased 18.12 9.87 92 824014 4929 89799412
Hysterectomy 18.08 9.87 50 824056 11534 89792807
Deafness 18.06 9.87 125 823981 22389 89781952
Atypical femur fracture 18.06 9.87 19 824087 6402 89797939
Back pain 18.06 9.87 2568 821538 314607 89489734
Coagulation factor X level decreased 18.05 9.87 10 824096 61 89804280
Transplant dysfunction 18.04 9.87 13 824093 5269 89799072
Metastases to central nervous system 18.01 9.87 90 824016 17452 89786889
Gastrooesophageal reflux disease 17.91 9.87 1286 822820 165051 89639290
Torsade de pointes 17.91 9.87 74 824032 15108 89789233
Ankle fracture 17.91 9.87 110 823996 20260 89784081
Knee operation 17.90 9.87 22 824084 6914 89797427
Acute kidney injury 17.90 9.87 2597 821509 317790 89486551
Liver transplant 17.89 9.87 54 824052 2263 89802078
Fluid retention 17.86 9.87 638 823468 87453 89716888
Ischaemic stroke 17.81 9.87 123 823983 22043 89782298
Breast cancer stage III 17.80 9.87 939 823167 83508 89720833
Arrhythmia 17.80 9.87 274 823832 42058 89762283
Haemarthrosis 17.79 9.87 7 824099 3987 89800354
Amniotic cavity disorder 17.79 9.87 10 824096 63 89804278
Live birth 17.78 9.87 885 823221 78222 89726119
Coordination abnormal 17.77 9.87 283 823823 21073 89783268
Pre-eclampsia 17.76 9.87 47 824059 11001 89793340
Adrenal insufficiency 17.72 9.87 180 823926 29741 89774600
Red blood cells urine positive 17.68 9.87 67 824039 3158 89801183
Mental impairment 17.62 9.87 85 824021 16635 89787706
Pharyngeal oedema 17.60 9.87 65 824041 13706 89790635
Antidepressant drug level above therapeutic 17.59 9.87 22 824084 468 89803873
Panic attack 17.59 9.87 154 823952 26211 89778130
Uterine cancer 17.44 9.87 14 824092 5371 89798970
Hypertriglyceridaemia 17.40 9.87 28 824078 7861 89796480
Disorientation 17.39 9.87 289 823817 43825 89760516
Neuroblastoma recurrent 17.35 9.87 14 824092 171 89804170
Nasal necrosis 17.33 9.87 12 824094 114 89804227
Onychomycosis 17.33 9.87 454 823652 36922 89767419
Bronchopulmonary aspergillosis 17.20 9.87 50 824056 11348 89792993
Nephrotic syndrome 17.19 9.87 25 824081 7314 89797027
Intervertebral discitis 17.14 9.87 84 824022 4436 89799905
Product monitoring error 17.13 9.87 10 824096 4534 89799807
Metastases to lymph nodes 17.12 9.87 52 824054 11637 89792704
Hypophagia 17.08 9.87 227 823879 35710 89768631
Reversible airways obstruction 17.03 9.87 48 824058 1935 89802406
Accidental death 17.03 9.87 49 824057 1999 89802342
Total lung capacity decreased 16.96 9.87 74 824032 3721 89800620
Abdominal pain lower 16.87 9.87 184 823922 29993 89774348
Glomerular filtration rate increased 16.85 9.87 49 824057 2011 89802330
Inappropriate antidiuretic hormone secretion 16.80 9.87 106 824000 19399 89784942
Stress fracture 16.79 9.87 33 824073 8578 89795763
Hepatic cyst 16.78 9.87 21 824085 6547 89797794
Dislocation of vertebra 16.77 9.87 645 823461 55323 89749018
Hepatic function abnormal 16.72 9.87 308 823798 45980 89758361
Hypoacusis 16.72 9.87 167 823939 27683 89776658
Wrong technique in device usage process 16.71 9.87 17 824089 5818 89798523
Ventricular tachycardia 16.62 9.87 144 823962 24564 89779777
Lung infiltration 16.50 9.87 77 824029 15205 89789136
Caesarean section 16.50 9.87 100 824006 18477 89785864
Harlequin syndrome 16.48 9.87 15 824091 218 89804123
Anuria 16.40 9.87 74 824032 14744 89789597
Administration site bruise 16.32 9.87 21 824085 460 89803881
Injection site vesicles 16.18 9.87 9 824097 4191 89800150
Underdose 16.09 9.87 371 823735 53646 89750695
Spinal compression fracture 16.08 9.87 77 824029 15101 89789240
Graft versus host disease in gastrointestinal tract 16.06 9.87 10 824096 4378 89799963
Systemic candida 15.93 9.87 13 824093 4946 89799395
Hypersensitivity vasculitis 15.90 9.87 9 824097 4150 89800191
Catatonia 15.85 9.87 19 824087 6037 89798304
Dry mouth 15.85 9.87 1909 822197 182150 89622191
Coagulation factor VII level decreased 15.85 9.87 10 824096 80 89804261
Urinary incontinence 15.84 9.87 243 823863 37323 89767018
Somnambulism 15.82 9.87 20 824086 6208 89798133
Injection site haematoma 15.80 9.87 24 824082 6898 89797443
Breast cancer recurrent 15.80 9.87 16 824090 5487 89798854
Bronchopulmonary aspergillosis allergic 15.75 9.87 72 824034 3694 89800647
Body temperature fluctuation 15.71 9.87 51 824055 2224 89802117
Potentiating drug interaction 15.65 9.87 17 824089 5645 89798696
Maternal exposure before pregnancy 15.63 9.87 51 824055 11162 89793179
Acute generalised exanthematous pustulosis 15.62 9.87 192 823914 13511 89790830
Injection site irritation 15.61 9.87 19 824087 5996 89798345
Laboratory test abnormal 15.59 9.87 277 823829 41577 89762764
Dermatitis allergic 15.53 9.87 93 824013 17234 89787107
Oropharyngeal discomfort 15.53 9.87 122 823984 7613 89796728
Hypoglycaemic coma 15.52 9.87 4 824102 2986 89801355
Tumour marker increased 15.43 9.87 18 824088 5789 89798552
Movement disorder 15.41 9.87 179 823927 28840 89775501
Emotional disorder 15.36 9.87 77 824029 14920 89789421
Red blood cell count decreased 15.35 9.87 313 823793 46038 89758303
Transaminases increased 15.33 9.87 445 823661 36747 89767594
Self-medication 15.33 9.87 64 824042 3156 89801185
Sudden infant death syndrome 15.32 9.87 17 824089 317 89804024
Papule 15.32 9.87 31 824075 7971 89796370
Human herpesvirus 6 infection 15.32 9.87 6 824100 3426 89800915
Nutritional supplementation 15.25 9.87 8 824098 43 89804298
Onychomadesis 15.21 9.87 536 823570 45462 89758879
Infusion site urticaria 15.21 9.87 42 824064 1673 89802668
Graft versus host disease 15.21 9.87 32 824074 8112 89796229
Blood prolactin increased 15.20 9.87 7 824099 3630 89800711
Bradypnoea 15.19 9.87 83 824023 4575 89799766
Impaired work ability 15.16 9.87 108 823998 19218 89785123
Unresponsive to stimuli 15.14 9.87 454 823652 37667 89766674
Endocarditis enterococcal 15.13 9.87 15 824091 244 89804097
Metabolic disorder 15.11 9.87 28 824078 7442 89796899
Blood triglycerides increased 15.06 9.87 69 824037 13692 89790649
Aortic valve stenosis 15.06 9.87 10 824096 4230 89800111
Peritonitis 15.03 9.87 111 823995 19594 89784747
Bone lesion 15.01 9.87 22 824084 6415 89797926
Neoplasm 14.99 9.87 37 824069 8866 89795475
Infusion site irritation 14.96 9.87 36 824070 1317 89803024
Tooth extraction 14.94 9.87 54 824052 11459 89792882
Klebsiella infection 14.94 9.87 46 824060 10251 89794090
Nail bed inflammation 14.89 9.87 43 824063 1758 89802583
Nephropathy toxic 14.87 9.87 62 824044 12626 89791715
Frostbite 14.81 9.87 14 824092 214 89804127
Nervousness 14.81 9.87 219 823887 33837 89770504
Maternal exposure timing unspecified 14.80 9.87 287 823819 22196 89782145
COVID-19 14.78 9.87 1753 822353 167090 89637251
Drug provocation test 14.77 9.87 7 824099 29 89804312
Cystitis haemorrhagic 14.75 9.87 17 824089 5496 89798845
Squamous cell carcinoma 14.74 9.87 45 824061 10056 89794285
Eyelid ptosis 14.72 9.87 38 824068 8968 89795373
Acne 14.69 9.87 177 823929 28330 89776011
Myopathy 14.67 9.87 68 824038 13450 89790891
Adjustment disorder 14.63 9.87 143 823963 9499 89794842
Snoring 14.61 9.87 15 824091 5111 89799230
Laryngospasm 14.59 9.87 6 824100 3327 89801014
Anhedonia 14.58 9.87 54 824052 11377 89792964
Nasal obstruction 14.55 9.87 3 824103 2609 89801732
Muscle disorder 14.54 9.87 17 824089 5462 89798879
Cerebral ischaemia 14.54 9.87 27 824079 7169 89797172
Metastases to peritoneum 14.49 9.87 10 824096 4145 89800196
Malignant melanoma 14.40 9.87 62 824044 12514 89791827
Sinus rhythm 14.39 9.87 36 824070 1350 89802991
Anosognosia 14.38 9.87 7 824099 3515 89800826
Coronary arterial stent insertion 14.37 9.87 4 824102 2836 89801505
Foreign body sensation in eyes 14.35 9.87 6 824100 3294 89801047
Pulmonary arterial pressure increased 14.23 9.87 9 824097 3907 89800434
Glycosylated haemoglobin increased 14.23 9.87 83 824023 15479 89788862
Sensory disturbance 14.20 9.87 82 824024 15331 89789010
BK virus infection 14.19 9.87 12 824094 4486 89799855
Ketoacidosis 14.18 9.87 18 824088 5577 89798764
Cardiogenic shock 14.16 9.87 148 823958 24320 89780021
Immunosuppressant drug level increased 14.14 9.87 13 824093 4667 89799674
Retinal haemorrhage 14.13 9.87 19 824087 5745 89798596
Mycobacterium avium complex infection 14.11 9.87 10 824096 4088 89800253
Clostridium difficile infection 14.11 9.87 238 823868 36007 89768334
Blood glucose abnormal 14.06 9.87 42 824064 9450 89794891
Cholecystectomy 14.05 9.87 57 824049 11698 89792643
Meniscus injury 14.05 9.87 34 824072 8203 89796138
Hyperthyroidism 14.03 9.87 103 824003 18207 89786134
Nervous system disorder 14.02 9.87 127 823979 21466 89782875
Application site erythema 14.00 9.87 16 824090 5192 89799149
Premature rupture of membranes 13.96 9.87 18 824088 5540 89798801
Blindness unilateral 13.94 9.87 31 824075 7705 89796636
Ejection fraction decreased 13.92 9.87 162 823944 26091 89778250
SJS-TEN overlap 13.92 9.87 31 824075 1077 89803264
Aplasia pure red cell 13.91 9.87 16 824090 5178 89799163
Lupus vulgaris 13.91 9.87 521 823585 44538 89759803
Occupational exposure to product 13.90 9.87 3 824103 2528 89801813
Therapy non-responder 13.90 9.87 1062 823044 135642 89668699
Proteinuria 13.84 9.87 140 823966 23151 89781190
Nerve injury 13.82 9.87 53 824053 11053 89793288
Post cholecystectomy syndrome 13.82 9.87 27 824079 854 89803487
Blood bilirubin increased 13.75 9.87 504 823602 42966 89761375
Pneumonia aspiration 13.69 9.87 276 823830 40664 89763677
Blindness 13.68 9.87 165 823941 26403 89777938
Drug screen positive 13.67 9.87 69 824037 3688 89800653
Polyomavirus-associated nephropathy 13.58 9.87 3 824103 2487 89801854
Gastric cancer 13.56 9.87 16 824090 5120 89799221
Blood loss anaemia 13.54 9.87 47 824059 10093 89794248
Pulmonary alveolar haemorrhage 13.50 9.87 21 824085 5977 89798364
Exposure to SARS-CoV-2 13.49 9.87 51 824055 2401 89801940
Rotator cuff syndrome 13.46 9.87 87 824019 15832 89788509
Blood glucose decreased 13.44 9.87 142 823964 23287 89781054
Gastroenteritis 13.40 9.87 186 823920 29043 89775298
Accidental poisoning 13.36 9.87 28 824078 932 89803409
Bladder cancer 13.35 9.87 20 824086 5781 89798560
Gout 13.33 9.87 94 824012 16765 89787576
Bruxism 13.33 9.87 12 824094 4351 89799990
Thirst 13.30 9.87 90 824016 16205 89788136
Drooling 13.30 9.87 13 824093 4533 89799808
Focal dyscognitive seizures 13.22 9.87 6 824100 3138 89801203
Transfusion-related acute lung injury 13.20 9.87 12 824094 174 89804167
Accidental exposure to product by child 13.19 9.87 34 824072 1299 89803042
SARS-CoV-2 test positive 13.15 9.87 157 823949 10971 89793370
Acute fatty liver of pregnancy 13.14 9.87 7 824099 39 89804302
Goitre 13.14 9.87 26 824080 6741 89797600
Bipolar disorder 13.14 9.87 40 824066 8945 89795396
Intraocular pressure increased 13.14 9.87 28 824078 7065 89797276
Intestinal obstruction 13.12 9.87 248 823858 36883 89767458
Pollakiuria 13.08 9.87 216 823890 32789 89771552
Rash macular 13.07 9.87 195 823911 30085 89774256
Epstein-Barr virus associated lymphoproliferative disorder 13.04 9.87 4 824102 2663 89801678
Cyanosis neonatal 12.98 9.87 18 824088 425 89803916
Therapy change 12.93 9.87 36 824070 8286 89796055
Stress cardiomyopathy 12.88 9.87 70 824036 13285 89791056
Alpha 1 microglobulin increased 12.86 9.87 7 824099 41 89804300
Intervertebral disc degeneration 12.85 9.87 98 824008 17176 89787165
Akathisia 12.79 9.87 55 824051 11104 89793237
Vertigo 12.74 9.87 512 823594 69299 89735042
Erysipelas 12.74 9.87 41 824065 9011 89795330
Diastolic dysfunction 12.72 9.87 30 824076 7303 89797038
Cells in urine 12.72 9.87 12 824094 183 89804158
Post procedural pulmonary embolism 12.70 9.87 13 824093 220 89804121
Congestive hepatopathy 12.70 9.87 58 824048 2975 89801366
Affective disorder 12.64 9.87 33 824073 7760 89796581
Respiratory symptom 12.63 9.87 12 824094 4240 89800101
Abdominal distension 12.59 9.87 1019 823087 129582 89674759
Coagulation factor V level decreased 12.59 9.87 16 824090 346 89803995
Abnormal loss of weight 12.58 9.87 27 824079 6796 89797545
Product dispensing error 12.58 9.87 63 824043 12210 89792131
Malnutrition 12.55 9.87 108 823998 18450 89785891
Toxic epidermal necrolysis 12.55 9.87 386 823720 32142 89772199
Neoplasm recurrence 12.53 9.87 7 824099 3252 89801089
Ovarian cyst 12.53 9.87 99 824007 17219 89787122
Necrotic lymphadenopathy 12.40 9.87 10 824096 122 89804219
Orbital compartment syndrome 12.38 9.87 9 824097 93 89804248
Bacterial test 12.37 9.87 30 824076 1103 89803238
Nocardiosis 12.31 9.87 4 824102 2566 89801775
Asthenia 12.31 9.87 4513 819593 529238 89275103
Haemoglobin urine present 12.31 9.87 24 824082 758 89803583
Opiates positive 12.29 9.87 15 824091 311 89804030
Dystonia 12.24 9.87 96 824010 16723 89787618
Candida infection 12.18 9.87 227 823879 33830 89770511
Anti-cyclic citrullinated peptide antibody 12.14 9.87 329 823777 26892 89777449
Tachyarrhythmia 12.10 9.87 19 824087 5387 89798954
Haemorrhage subcutaneous 12.08 9.87 8 824098 3388 89800953
Cachexia 12.04 9.87 28 824078 6850 89797491
Poor quality device used 12.04 9.87 3 824103 2290 89802051
Hepatitis B 12.02 9.87 14 824092 4505 89799836
Leukoencephalopathy 12.01 9.87 16 824090 4857 89799484
Jaw disorder 12.01 9.87 20 824086 5539 89798802
Secretion discharge 11.91 9.87 90 824016 15806 89788535
Infusion site discomfort 11.90 9.87 40 824066 1776 89802565
Cardiac operation 11.90 9.87 11 824095 3938 89800403
Urinary casts 11.88 9.87 24 824082 778 89803563
Concomitant disease aggravated 11.88 9.87 59 824047 11459 89792882
Body height decreased 11.87 9.87 62 824044 11887 89792454
Catheter site bruise 11.83 9.87 20 824086 564 89803777
Crying 11.82 9.87 163 823943 25482 89778859
Pulmonary tuberculosis 11.79 9.87 16 824090 4818 89799523
Diverticulum intestinal 11.79 9.87 43 824063 9099 89795242
Febrile bone marrow aplasia 11.78 9.87 47 824059 9691 89794650
Sickle cell anaemia with crisis 11.76 9.87 31 824075 7266 89797075
Costovertebral angle tenderness 11.75 9.87 11 824095 166 89804175
Neurological examination normal 11.74 9.87 7 824099 50 89804291
Hepatic lesion 11.71 9.87 21 824085 5652 89798689
Carotid artery stenosis 11.70 9.87 19 824087 5315 89799026
Glutathione decreased 11.62 9.87 6 824100 31 89804310
Enterococcal infection 11.60 9.87 49 824057 9942 89794399
Base excess 11.52 9.87 7 824099 52 89804289
Catheterisation cardiac 11.49 9.87 17 824089 4939 89799402
Macular degeneration 11.47 9.87 438 823668 37532 89766809
Dyslipidaemia 11.47 9.87 50 824056 10057 89794284
Application site pruritus 11.47 9.87 13 824093 4234 89800107
Hereditary angioedema 11.46 9.87 45 824061 9320 89795021
Granulocytopenia 11.46 9.87 26 824080 6415 89797926
Jaw fracture 11.44 9.87 5 824101 2673 89801668
Device kink 11.43 9.87 3 824103 2212 89802129
Application site rash 11.37 9.87 5 824101 2664 89801677
Nasal ulcer 11.35 9.87 5 824101 2661 89801680
Paradoxical drug reaction 11.33 9.87 22 824084 5744 89798597
Supraventricular extrasystoles 11.27 9.87 19 824087 5238 89799103
Substance abuse 11.26 9.87 86 824020 5320 89799021
Eosinophil percentage increased 11.23 9.87 27 824079 987 89803354
Stent placement 11.20 9.87 13 824093 4190 89800151
Skin fissures 11.19 9.87 128 823978 20681 89783660
Labelled drug-drug interaction medication error 11.19 9.87 82 824024 14500 89789841
Band neutrophil percentage increased 11.19 9.87 12 824094 215 89804126
Blood urine present 11.18 9.87 220 823886 17058 89787283
Coma hepatic 11.17 9.87 21 824085 645 89803696
Road traffic accident 11.15 9.87 1130 822976 106496 89697845
Balint's syndrome 11.13 9.87 3 824103 0 89804341
Inappropriate schedule of product administration 11.12 9.87 1541 822565 148392 89655949
Asphyxia 11.10 9.87 106 824000 6997 89797344
Eye pain 11.10 9.87 311 823795 43857 89760484
Peptic ulcer perforation 11.08 9.87 17 824089 441 89803900
Dysuria 11.07 9.87 273 823833 39128 89765213
Condition aggravated 11.07 9.87 5074 819032 590471 89213870
Band neutrophil count increased 11.07 9.87 16 824090 393 89803948
Regurgitation 11.05 9.87 3 824103 2163 89802178
Pneumatosis intestinalis 11.05 9.87 9 824097 3428 89800913
Hepatitis 11.04 9.87 766 823340 69973 89734368
Obstructive airways disorder 11.03 9.87 167 823939 25702 89778639
Photosensitivity reaction 11.02 9.87 106 824000 17701 89786640
Ankle arthroplasty 11.01 9.87 6 824100 2825 89801516
Catheter management 11.00 9.87 7 824099 3029 89801312
Agonal respiration 10.99 9.87 11 824095 181 89804160
Tongue disorder 10.99 9.87 56 824050 10804 89793537
Bladder prolapse 10.97 9.87 3 824103 2152 89802189
Kidney transplant rejection 10.94 9.87 17 824089 4840 89799501
Administration site erythema 10.94 9.87 25 824081 884 89803457
Foetal growth restriction 10.89 9.87 46 824060 9334 89795007
Non-cardiogenic pulmonary oedema 10.88 9.87 30 824076 1194 89803147
Myelocyte count increased 10.86 9.87 16 824090 400 89803941
Nonspecific reaction 10.85 9.87 6 824100 2803 89801538
Metastases to skin 10.85 9.87 3 824103 2137 89802204
Partial seizures 10.84 9.87 32 824074 7228 89797113
Arthrodesis 10.84 9.87 7 824099 3005 89801336
Haemorrhage intracranial 10.82 9.87 87 824019 15075 89789266
Peritonitis bacterial 10.81 9.87 19 824087 5152 89799189
Acute coronary syndrome 10.80 9.87 56 824050 10757 89793584
Tongue biting 10.80 9.87 3 824103 2130 89802211
Onychoclasis 10.77 9.87 33 824073 7366 89796975
Tetany 10.76 9.87 5 824101 2579 89801762
Prothrombin time prolonged 10.74 9.87 136 823970 9636 89794705
Aplastic anaemia 10.73 9.87 175 823931 13094 89791247
Hot flush 10.70 9.87 437 823669 59051 89745290
Electrocardiogram QRS complex prolonged 10.68 9.87 108 823998 7240 89797101
Vitamin D deficiency 10.65 9.87 105 824001 17451 89786890
Nephrogenic systemic fibrosis 10.63 9.87 13 824093 4095 89800246
Hepatitis toxic 10.60 9.87 64 824042 3661 89800680
Foot fracture 10.59 9.87 174 823932 26432 89777909
Status epilepticus 10.58 9.87 115 823991 18759 89785582
Metabolic myopathy 10.57 9.87 9 824097 119 89804222
Blood creatinine decreased 10.57 9.87 98 824008 6417 89797924
Prothrombin level decreased 10.56 9.87 21 824085 673 89803668
Metabolic alkalosis 10.56 9.87 10 824096 3539 89800802
Tachycardia 10.55 9.87 1611 822495 156062 89648279
Stoma site dermatitis 10.52 9.87 13 824093 273 89804068
Lung opacity 10.52 9.87 93 824013 6009 89798332
Lymphocyte count decreased 10.51 9.87 404 823702 34646 89769695
Hepatic perfusion disorder 10.51 9.87 7 824099 62 89804279
Haematemesis 10.51 9.87 230 823876 33496 89770845
Erythema 10.41 9.87 1880 822226 227366 89576975
Creatinine renal clearance increased 10.39 9.87 58 824048 3223 89801118
Diffuse axonal injury 10.38 9.87 8 824098 91 89804250
Sinus node dysfunction 10.33 9.87 21 824085 5391 89798950
Lung transplant 10.30 9.87 11 824095 3681 89800660
Restless legs syndrome 10.30 9.87 143 823963 22327 89782014
Granulocyte count increased 10.24 9.87 34 824072 1500 89802841
Acute myeloid leukaemia recurrent 10.21 9.87 3 824103 2054 89802287
Disseminated tuberculosis 10.16 9.87 9 824097 3290 89801051
Hypotonic-hyporesponsive episode 10.14 9.87 5 824101 23 89804318
Infusion site warmth 10.14 9.87 43 824063 2135 89802206
Fatigue 10.13 9.87 10039 814067 1143984 88660357
Dysphagia 10.08 9.87 881 823225 111397 89692944
Hyporesponsive to stimuli 10.06 9.87 35 824071 1582 89802759
Essential hypertension 10.05 9.87 27 824079 6288 89798053
Increased tendency to bruise 10.05 9.87 65 824041 11825 89792516
Abnormal behaviour 10.02 9.87 145 823961 22483 89781858
Foetal heart rate abnormal 10 9.87 25 824081 937 89803404
White coat hypertension 9.99 9.87 26 824080 999 89803342
Infusion site discolouration 9.99 9.87 27 824079 1062 89803279
Eructation 9.97 9.87 58 824048 10824 89793517
Parosmia 9.96 9.87 32 824074 7037 89797304
Intraductal proliferative breast lesion 9.96 9.87 10 824096 3443 89800898
Anti-neutrophil cytoplasmic antibody positive vasculitis 9.96 9.87 13 824093 3980 89800361
Transferrin decreased 9.95 9.87 15 824091 383 89803958
Gingival disorder 9.95 9.87 13 824093 3978 89800363
Hepatitis C 9.94 9.87 23 824083 5637 89798704
Arterial intramural haematoma 9.92 9.87 10 824096 166 89804175
Subdural haematoma 9.91 9.87 100 824006 16545 89787796
Disseminated intravascular coagulation 9.89 9.87 137 823969 21401 89782940
Walking aid user 9.89 9.87 406 823700 35100 89769241

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 2504.89 10.76 4934 270679 224202 42121520
Completed suicide 1693.72 10.76 2566 273047 93899 42251823
Exposure to toxic agent 1196.68 10.76 604 275009 4400 42341322
Intentional overdose 812.86 10.76 1305 274308 50151 42295571
Overdose 710.17 10.76 1877 273736 103387 42242335
Acute hepatic failure 593.84 10.76 639 274974 16434 42329288
Intentional product misuse 515.64 10.76 1197 274416 60703 42285019
Infusion related reaction 448.63 10.76 1122 274491 59684 42286038
Drug abuse 411.66 10.76 1550 274063 103221 42242501
Blood pressure fluctuation 398.34 10.76 663 274950 26245 42319477
Hepatic cytolysis 375.60 10.76 645 274968 26199 42319523
Drug ineffective 357.20 10.76 2502 273111 627695 41718027
Suicide attempt 318.52 10.76 830 274783 45270 42300452
Cytokine release syndrome 280.71 10.76 775 274838 43752 42301970
Metabolic acidosis 244.51 10.76 815 274798 51043 42294679
Analgesic drug level increased 205.86 10.76 113 275500 995 42344727
Heart rate decreased 202.31 10.76 607 275006 35925 42309797
Suspected suicide 199.85 10.76 223 275390 5976 42339746
Poisoning deliberate 198.09 10.76 284 275329 9850 42335872
Medication error 160.65 10.76 526 275087 32628 42313094
Pyroglutamic acidosis 159.63 10.76 85 275528 700 42345022
Accidental overdose 158.06 10.76 472 275141 27858 42317864
Myocardial infarction 153.94 10.76 360 275253 123649 42222073
Febrile neutropenia 150.67 10.76 1849 273764 183854 42161868
Blood pressure increased 145.22 10.76 1142 274471 100786 42244936
Drug resistance 137.72 10.76 27 275586 34221 42311501
Poisoning 134.23 10.76 295 275318 14404 42331318
Liver injury 129.37 10.76 342 275271 18806 42326916
Coagulopathy 125.29 10.76 371 275242 21791 42323931
Methaemoglobinaemia 125.05 10.76 170 275443 5604 42340118
Myelosuppression 124.10 10.76 53 275560 40408 42305314
Anion gap 112.36 10.76 69 275544 764 42344958
Product dose omission issue 111.99 10.76 565 275048 153800 42191922
Oxygen saturation decreased 109.35 10.76 755 274858 63932 42281790
Diarrhoea 109.27 10.76 2214 273399 458635 41887087
Suspected suicide attempt 108.79 10.76 52 275561 331 42345391
Blood pressure systolic increased 108.16 10.76 412 275201 27556 42318166
Intentional product use issue 106.24 10.76 812 274801 71021 42274701
Cardiac failure congestive 103.41 10.76 252 275361 85350 42260372
Treatment failure 102.18 10.76 154 275459 62470 42283252
Inspiratory capacity decreased 101.29 10.76 110 275503 2857 42342865
Therapeutic product effect incomplete 97.90 10.76 194 275419 70745 42274977
Injection site pain 94.43 10.76 142 275471 57656 42288066
Hepatitis fulminant 89.71 10.76 134 275479 4825 42340897
Cardio-respiratory arrest 88.48 10.76 666 274947 57970 42287752
Respiratory arrest 88.02 10.76 391 275222 28033 42317689
Blood pressure diastolic abnormal 87.99 10.76 149 275464 5979 42339743
Fixed eruption 83.81 10.76 91 275522 2363 42343359
Hepatotoxicity 82.36 10.76 352 275261 24815 42320907
Cardiac failure 78.08 10.76 390 275223 106466 42239256
Tachycardia 75.65 10.76 992 274621 100095 42245627
Chills 75.44 10.76 935 274678 93131 42252591
Toxic epidermal necrolysis 73.99 10.76 356 275257 26394 42319328
Depressed level of consciousness 73.58 10.76 547 275066 47423 42298299
COVID-19 73.55 10.76 1105 274508 114843 42230879
Coma 73.45 10.76 595 275018 52959 42292763
Respiratory depression 72.17 10.76 277 275336 18591 42327131
Renal impairment 70.80 10.76 420 275193 109808 42235914
Serotonin syndrome 69.36 10.76 341 275272 25504 42320218
Body temperature decreased 66.53 10.76 225 275388 14188 42331534
Hepatitis acute 66.51 10.76 166 275447 8809 42336913
Disease progression 63.42 10.76 608 275005 143048 42202674
Infusion site extravasation 60.59 10.76 119 275494 5362 42340360
Hypotension 60.48 10.76 2133 273480 255498 42090224
Blood pressure diastolic increased 60.13 10.76 130 275483 6275 42339447
Sleep disorder due to a general medical condition 58.27 10.76 20 275593 17433 42328289
Generalised bullous fixed drug eruption 57.69 10.76 36 275577 411 42345311
Blood pressure systolic abnormal 57.49 10.76 117 275496 5411 42340311
Wrong technique in product usage process 56.76 10.76 119 275494 42516 42303206
Vomiting 54.40 10.76 2341 273272 287382 42058340
Inappropriate schedule of product administration 52.89 10.76 893 274720 95009 42250713
Asthenia 52.29 10.76 1399 274214 279394 42066328
Therapeutic response decreased 52.10 10.76 100 275513 36912 42308810
Somnolence 51.16 10.76 1234 274379 139871 42205851
Prothrombin time ratio decreased 50.93 10.76 37 275576 552 42345170
Dizziness 50.65 10.76 1226 274387 248028 42097694
Appendicolith 50.20 10.76 196 275417 13260 42332462
Nightmare 49.61 10.76 304 275309 24708 42321014
Hepatic necrosis 49.51 10.76 90 275523 3823 42341899
Stevens-Johnson syndrome 48.79 10.76 277 275336 21901 42323821
Obstructive airways disorder 48.53 10.76 53 275560 24706 42321016
Pharyngeal paraesthesia 48.45 10.76 43 275570 866 42344856
Lymphocyte count abnormal 48.29 10.76 65 275548 2122 42343600
Exposure via ingestion 48.28 10.76 64 275549 2058 42343664
Vanishing bile duct syndrome 48.18 10.76 60 275553 1811 42343911
Blood pressure diastolic decreased 47.92 10.76 162 275451 10213 42335509
Hospitalisation 47.82 10.76 283 275330 74047 42271675
Prostate cancer 47.41 10.76 140 275473 44503 42301219
Depression 46.76 10.76 477 275136 110886 42234836
Body temperature increased 46.60 10.76 257 275356 20101 42325621
Cholestatic liver injury 46.54 10.76 85 275528 3624 42342098
Malignant neoplasm progression 46.47 10.76 462 275151 107938 42237784
Heart rate irregular 46.12 10.76 216 275397 15834 42329888
Alanine aminotransferase increased 45.79 10.76 815 274798 87591 42258131
Mixed liver injury 45.71 10.76 94 275519 4380 42341342
Throat irritation 45.52 10.76 186 275427 12850 42332872
Delusion of grandeur 45.11 10.76 60 275553 1936 42343786
Dry skin 44.14 10.76 162 275451 48176 42297546
Renal cortical necrosis 43.96 10.76 23 275590 182 42345540
Hepatic failure 43.72 10.76 407 275206 37693 42308029
Fatigue 43.69 10.76 2338 273275 433303 41912419
Abdominal pain 43.16 10.76 1571 274042 188900 42156822
Therapeutic product effect decreased 42.87 10.76 121 275492 39029 42306693
Full blood count abnormal 42.68 10.76 80 275533 29796 42315926
Infusion site pain 42.33 10.76 102 275511 5293 42340429
Clostridium test positive 42.04 10.76 103 275510 5402 42340320
Substance abuse 41.97 10.76 140 275473 8765 42336957
Poor venous access 41.55 10.76 122 275491 7130 42338592
Eosinophilic granulomatosis with polyangiitis 41.32 10.76 4 275609 8634 42337088
Asthma 40.75 10.76 236 275377 62078 42283644
Drug-induced liver injury 40.05 10.76 401 275212 37872 42307850
Neuropathy peripheral 40.03 10.76 443 275170 101410 42244312
Product prescribing error 39.94 10.76 67 275546 26045 42319677
Coronary artery disease 39.83 10.76 195 275418 53525 42292197
Sinusitis 39.59 10.76 474 275139 46818 42298904
Dyspnoea 39.55 10.76 2402 273211 440219 41905503
Dyspnoea exertional 38.36 10.76 180 275433 49968 42295754
Cerebral haemorrhage 37.99 10.76 127 275486 38839 42306883
Memory impairment 37.99 10.76 181 275432 50041 42295681
Rhinalgia 37.99 10.76 53 275560 1791 42343931
Head discomfort 37.57 10.76 95 275518 5082 42340640
Feeling abnormal 37.21 10.76 281 275332 69505 42276217
Bone marrow failure 37.19 10.76 101 275512 32992 42312730
Graft versus host disease 36.44 10.76 19 275594 12906 42332816
Glycosylated haemoglobin increased 36.44 10.76 19 275594 12905 42332817
Appendicitis 36.24 10.76 243 275370 20370 42325352
Sedation 36.20 10.76 328 275285 30147 42315575
Aspartate aminotransferase increased 36.01 10.76 700 274913 76463 42269259
Hyperaesthesia 35.91 10.76 102 275511 5850 42339872
Decreased appetite 35.19 10.76 965 274648 192172 42153550
Acute myocardial infarction 35.05 10.76 226 275387 57939 42287783
Post transplant lymphoproliferative disorder 35.00 10.76 8 275605 9112 42336610
Therapy non-responder 34.93 10.76 202 275411 53157 42292565
Immune effector cell-associated neurotoxicity syndrome 34.63 10.76 137 275476 9324 42336398
Ductus arteriosus premature closure 34.39 10.76 21 275592 230 42345492
Heart rate increased 34.30 10.76 509 275104 52746 42292976
Pyrexia 34.25 10.76 2975 272638 391067 41954655
Respiratory rate increased 34.11 10.76 152 275461 10910 42334812
Bladder cancer 33.96 10.76 36 275577 17011 42328711
Anaphylactic reaction 33.44 10.76 423 275190 42320 42303402
Infusion site erythema 33.41 10.76 73 275540 3549 42342173
Asphyxia 33.30 10.76 124 275489 8202 42337520
Haematotoxicity 32.71 10.76 15 275598 10970 42334752
Prostatic specific antigen increased 32.33 10.76 37 275576 16888 42328834
Cerebral artery thrombosis 32.07 10.76 40 275573 1209 42344513
Anaemia 31.94 10.76 1484 274129 278794 42066928
Osteonecrosis of jaw 31.88 10.76 46 275567 19003 42326719
Accidental death 31.76 10.76 65 275548 3018 42342704
BK virus infection 31.23 10.76 9 275604 8775 42336947
Erectile dysfunction 31.13 10.76 72 275541 24841 42320881
Progressive multifocal leukoencephalopathy 31.01 10.76 18 275595 11518 42334204
Hyperphosphataemia 31.00 10.76 166 275447 12838 42332884
Forced expiratory volume decreased 30.70 10.76 6 275607 7624 42338098
Device leakage 30.70 10.76 14 275599 10271 42335451
Pathogen resistance 30.59 10.76 18 275595 11432 42334290
Hypoxia 30.53 10.76 627 274986 69159 42276563
Mydriasis 30.51 10.76 125 275488 8645 42337077
Acidosis 30.13 10.76 158 275455 12121 42333601
Cerebral infarction 30.10 10.76 102 275511 31067 42314655
Syncope 29.96 10.76 457 275156 98949 42246773
Blood phosphorus increased 29.93 10.76 160 275453 12365 42333357
Pulmonary vasculitis 29.71 10.76 3 275610 6263 42339459
Cerebrovascular accident 29.51 10.76 446 275167 96714 42249008
Injection site swelling 29.39 10.76 40 275573 16933 42328789
Injection site reaction 29.35 10.76 35 275578 15686 42330036
Monocyte chemotactic protein-1 increased 29.31 10.76 22 275591 346 42345376
Oesophageal carcinoma 29.25 10.76 13 275600 9683 42336039
Infusion site pruritus 29.22 10.76 37 275576 1136 42344586
Pancytopenia 29.12 10.76 561 275052 117182 42228540
Alpha tumour necrosis factor increased 29.05 10.76 22 275591 351 42345371
Drug ineffective for unapproved indication 29.03 10.76 177 275436 45986 42299736
Adulterated product 28.99 10.76 30 275583 736 42344986
Cardiac failure chronic 28.76 10.76 13 275600 9588 42336134
Pulmonary alveolar haemorrhage 28.72 10.76 32 275581 14784 42330938
Syringe issue 28.23 10.76 10 275603 8546 42337176
Psoriatic arthropathy 28.20 10.76 76 275537 24891 42320831
Ear pruritus 28.14 10.76 29 275584 708 42345014
Erythema multiforme 27.74 10.76 133 275480 9844 42335878
Dehydration 27.74 10.76 701 274912 141066 42204656
Cytomegalovirus infection 27.73 10.76 111 275502 32195 42313527
Drug dose omission by device 27.44 10.76 3 275610 5883 42339839
Therapy interrupted 27.24 10.76 65 275548 22185 42323537
Neuroblastoma recurrent 27.11 10.76 22 275591 390 42345332
Atrial fibrillation 27.11 10.76 691 274922 138902 42206820
Injection site haemorrhage 26.66 10.76 22 275591 11714 42334008
Infusion site swelling 26.65 10.76 63 275550 3229 42342493
Oedema peripheral 26.58 10.76 673 274940 135403 42210319
Physical deconditioning 26.32 10.76 52 275561 2353 42343369
Body temperature fluctuation 26.28 10.76 42 275571 1605 42344117
Cardiac disorder 26.10 10.76 197 275416 48735 42296987
Anion gap abnormal 25.98 10.76 22 275591 415 42345307
Myasthenia gravis 25.87 10.76 186 275427 15951 42329771
Product substitution issue 25.85 10.76 21 275592 11269 42334453
Injection site bruising 25.69 10.76 22 275591 11503 42334219
Immune reconstitution inflammatory syndrome 25.64 10.76 17 275596 10126 42335596
Therapy cessation 25.63 10.76 59 275554 20391 42325331
Urine sodium decreased 25.55 10.76 15 275598 152 42345570
Injection site erythema 25.53 10.76 58 275555 20137 42325585
Aplastic anaemia 25.50 10.76 152 275461 12232 42333490
Blood glucose increased 25.33 10.76 330 275283 73369 42272353
Myocardial fibrosis 25.31 10.76 36 275577 1239 42344483
Pemphigus 25.20 10.76 46 275567 1960 42343762
Dermatitis atopic 24.93 10.76 26 275587 12378 42333344
Osteonecrosis 24.92 10.76 40 275573 15825 42329897
Therapy partial responder 24.90 10.76 58 275555 19963 42325759
Skin exfoliation 24.75 10.76 162 275451 41391 42304331
Drug reaction with eosinophilia and systemic symptoms 24.73 10.76 396 275217 41679 42304043
Anxiety 24.62 10.76 581 275032 117979 42227743
Parvimonas micra infection 24.55 10.76 11 275602 59 42345663
Myopathy 24.26 10.76 32 275581 13729 42331993
Visual acuity reduced 24.19 10.76 48 275565 17502 42328220
Muscle spasms 24.11 10.76 401 275212 85643 42260079
Leukocytosis 24.09 10.76 296 275317 29412 42316310
Cardiac arrest 24.08 10.76 899 274714 108421 42237301
Hyperlactacidaemia 24.01 10.76 74 275539 4442 42341280
Sopor 24.00 10.76 30 275583 13172 42332550
Myalgia 23.99 10.76 457 275156 95623 42250099
Gait inability 23.95 10.76 72 275541 22761 42322961
Fall 23.72 10.76 1257 274356 233263 42112459
Postoperative delirium 23.61 10.76 24 275589 576 42345146
Inadequate analgesia 23.55 10.76 59 275554 3138 42342584
Injection site pruritus 23.46 10.76 16 275597 9389 42336333
Brain scan abnormal 23.16 10.76 34 275579 1205 42344517
Agitation 23.14 10.76 562 275051 63752 42281970
Substance-induced psychotic disorder 23.07 10.76 55 275558 2834 42342888
Conjunctivitis allergic 23.06 10.76 5 275608 5906 42339816
Sudden infant death syndrome 23.01 10.76 18 275595 302 42345420
Blood immunoglobulin G decreased 22.91 10.76 48 275565 2266 42343456
Contraindicated product administered 22.87 10.76 85 275528 25187 42320535
Gastrointestinal haemorrhage 22.84 10.76 470 275143 97256 42248466
C-reactive protein abnormal 22.77 10.76 16 275597 9245 42336477
Cholestasis 22.65 10.76 318 275295 32561 42313161
Peripheral swelling 22.65 10.76 429 275184 89841 42255881
Psoriasis 22.58 10.76 203 275410 48401 42297321
Venoocclusive liver disease 22.56 10.76 20 275593 10282 42335440
Cytopenia 22.32 10.76 50 275563 17447 42328275
Transaminases increased 22.23 10.76 317 275296 32568 42313154
Intraocular pressure increased 22.13 10.76 7 275606 6426 42339296
Vision blurred 22.11 10.76 231 275382 53468 42292254
Labelled drug-drug interaction medication error 22.01 10.76 42 275571 15540 42330182
Blood pH decreased 21.98 10.76 47 275566 2251 42343471
Injection site rash 21.94 10.76 5 275608 5707 42340015
No adverse event 21.81 10.76 155 275458 38866 42306856
Hepatitis C 21.80 10.76 20 275593 10113 42335609
Chronic graft versus host disease 21.74 10.76 6 275607 6019 42339703
Diabetic ketoacidosis 21.73 10.76 73 275540 22294 42323428
Transplant rejection 21.59 10.76 34 275579 13554 42332168
Drug use disorder 21.39 10.76 127 275486 10206 42335516
Balance disorder 21.27 10.76 201 275412 47444 42298278
Slow speech 21.18 10.76 40 275573 1750 42343972
Hypopnoea 21.14 10.76 104 275509 7778 42337944
Reversible cerebral vasoconstriction syndrome 21.12 10.76 25 275588 715 42345007
Nocardiosis 21.06 10.76 4 275609 5186 42340536
Chest pain 21.00 10.76 715 274898 138815 42206907
Neutrophil percentage increased 20.92 10.76 42 275571 1923 42343799
Acute graft versus host disease in skin 20.80 10.76 11 275602 7413 42338309
Graft versus host disease in gastrointestinal tract 20.79 10.76 4 275609 5139 42340583
Acute generalised exanthematous pustulosis 20.68 10.76 110 275503 8485 42337237
Enterocolitis infectious 20.65 10.76 42 275571 1941 42343781
Renal papillary necrosis 20.50 10.76 13 275600 153 42345569
Second primary malignancy 20.48 10.76 19 275594 9556 42336166
Iron deficiency 20.41 10.76 132 275481 10929 42334793
Aspergillus infection 20.41 10.76 45 275568 15792 42329930
Rhinitis 20.34 10.76 140 275473 11837 42333885
Insomnia 20.20 10.76 596 275017 117657 42228065
Gait disturbance 20.13 10.76 481 275132 97519 42248203
Tooth injury 20.10 10.76 32 275581 1219 42344503
Interleukin level increased 20.02 10.76 27 275586 883 42344839
Sleep disorder therapy 19.97 10.76 93 275520 6801 42338921
Product quality issue 19.77 10.76 55 275558 17827 42327895
Pulmonary fibrosis 19.68 10.76 97 275516 26584 42319138
SARS-CoV-2 test positive 19.39 10.76 105 275508 8155 42337567
Ventricular tachycardia 19.30 10.76 115 275498 30045 42315677
Infusion site bruising 19.07 10.76 27 275586 925 42344797
Ear infection 19.05 10.76 145 275468 12659 42333063
Alcohol poisoning 18.96 10.76 98 275515 7476 42338246
Stomatitis 18.93 10.76 221 275392 50108 42295614
Endophthalmitis 18.90 10.76 3 275610 4430 42341292
Epilepsy 18.82 10.76 96 275517 26075 42319647
Unevaluable event 18.78 10.76 137 275476 34151 42311571
Hypothermia 18.78 10.76 142 275471 12373 42333349
Ureteric haemorrhage 18.77 10.76 14 275599 218 42345504
Hypoaesthesia 18.74 10.76 337 275276 71126 42274596
Full blood count decreased 18.70 10.76 69 275544 20491 42325231
Flushing 18.68 10.76 340 275273 36688 42309034
Cytomegalovirus viraemia 18.43 10.76 24 275589 10353 42335369
Mononeuropathy 18.39 10.76 15 275598 268 42345454
Urticaria 18.31 10.76 617 274996 73419 42272303
Lung neoplasm malignant 18.26 10.76 63 275550 19084 42326638
Acute phase reaction 18.24 10.76 12 275601 151 42345571
Incorrect drug administration rate 18.21 10.76 42 275571 2118 42343604
Hypothyroidism 18.15 10.76 127 275486 31957 42313765
Chronic gastrointestinal bleeding 18.00 10.76 16 275597 323 42345399
Acute graft versus host disease 17.93 10.76 16 275597 8199 42337523
Nasal septum perforation 17.84 10.76 14 275599 236 42345486
Cytomegalovirus chorioretinitis 17.78 10.76 4 275609 4607 42341115
Rash maculo-papular 17.75 10.76 341 275272 37162 42308560
Psychiatric decompensation 17.68 10.76 3 275610 4219 42341503
International normalised ratio increased 17.65 10.76 422 275191 47746 42297976
Neuralgia 17.65 10.76 248 275365 25399 42320323
Sexual dysfunction 17.61 10.76 11 275602 6764 42338958
Cystitis haemorrhagic 17.58 10.76 13 275600 7316 42338406
Acute myeloid leukaemia 17.54 10.76 79 275534 22177 42323545
Blood triglycerides increased 17.49 10.76 49 275564 15847 42329875
Hyperthermia 17.39 10.76 140 275473 12434 42333288
Throat tightness 17.38 10.76 114 275499 9485 42336237
Brain death 17.34 10.76 51 275562 2983 42342739
Hyperhidrosis 17.28 10.76 733 274880 89779 42255943
Laboratory test abnormal 17.26 10.76 83 275530 22895 42322827
Rash 17.24 10.76 1549 274064 275405 42070317
Mechanical ventilation complication 17.21 10.76 22 275591 682 42345040
Prostatic pain 17.21 10.76 16 275597 343 42345379
Injection site mass 17.20 10.76 18 275595 8557 42337165
Transfusion-related circulatory overload 17.20 10.76 23 275590 746 42344976
Aminoaciduria 17.17 10.76 14 275599 250 42345472
Bilirubin urine present 17.16 10.76 12 275601 168 42345554
Electrocardiogram QT prolonged 17.10 10.76 213 275400 47732 42297990
Pyroglutamate increased 16.99 10.76 15 275598 300 42345422
Lymphocyte percentage decreased 16.97 10.76 42 275571 2217 42343505
Self-medication 16.89 10.76 53 275560 3213 42342509
Neglect of personal appearance 16.80 10.76 16 275597 354 42345368
Akathisia 16.75 10.76 26 275587 10425 42335297
Fibrin D dimer increased 16.52 10.76 70 275543 4915 42340807
Symmetrical drug-related intertriginous and flexural exanthema 16.49 10.76 24 275589 844 42344878
Patient uncooperative 16.45 10.76 21 275592 650 42345072
Hepatitis 16.44 10.76 258 275355 27042 42318680
Systemic lupus erythematosus 16.44 10.76 110 275503 9214 42336508
Ductus arteriosus stenosis foetal 16.41 10.76 12 275601 181 42345541
Tuberculosis 16.30 10.76 25 275588 10074 42335648
Prothrombin time abnormal 16.17 10.76 24 275589 859 42344863
Accidental exposure to product by child 16.10 10.76 33 275580 1534 42344188
Areflexia 16.03 10.76 57 275556 3686 42342036
Sulphaemoglobinaemia 16.02 10.76 7 275606 35 42345687
Granulomatosis with polyangiitis 16.02 10.76 32 275581 1460 42344262
Pain in extremity 16.01 10.76 803 274810 149801 42195921
Migraine 16.01 10.76 242 275371 25172 42320550
Emotional distress 15.99 10.76 52 275561 16041 42329681
Vital functions abnormal 15.98 10.76 16 275597 377 42345345
Pruritus 15.98 10.76 1029 274584 187742 42157980
Thrombotic microangiopathy 15.95 10.76 46 275567 14736 42330986
Infusion site mass 15.95 10.76 16 275597 378 42345344
Normochromic normocytic anaemia 15.92 10.76 21 275592 9010 42336712
Angina pectoris 15.90 10.76 136 275477 32760 42312962
Oedematous pancreatitis 15.87 10.76 22 275591 739 42344983
Confusion postoperative 15.79 10.76 11 275602 153 42345569
Brain injury 15.79 10.76 94 275519 7561 42338161
Acute lung injury 15.78 10.76 33 275580 1556 42344166
Cerebral palsy 15.78 10.76 16 275597 383 42345339
Low birth weight baby 15.73 10.76 25 275588 9930 42335792
Infusion site discomfort 15.68 10.76 16 275597 386 42345336
Drug therapy 15.59 10.76 82 275531 6298 42339424
Adenocarcinoma of colon 15.53 10.76 3 275610 3844 42341878
Type 2 diabetes mellitus 15.52 10.76 64 275549 18407 42327315
Retinal haemorrhage 15.52 10.76 9 275604 5761 42339961
Coagulation factor V level decreased 15.45 10.76 13 275600 243 42345479
Hemiparesis 15.36 10.76 59 275554 17317 42328405
Interstitial lung disease 15.32 10.76 388 275225 78074 42267648
Renal disorder 15.29 10.76 117 275496 28863 42316859
Product complaint 15.13 10.76 10 275603 5967 42339755
Miosis 15.10 10.76 143 275470 13303 42332419
Immunoglobulin G4 related disease 15.10 10.76 13 275600 251 42345471
Consciousness fluctuating 15.08 10.76 29 275584 1286 42344436
Anti factor V antibody 15.02 10.76 14 275599 301 42345421
Unresponsive to stimuli 15.02 10.76 286 275327 31117 42314605
Infusion site rash 15.02 10.76 20 275593 646 42345076
Hyper IgE syndrome 14.98 10.76 11 275602 167 42345555
Anti-erythrocyte antibody positive 14.85 10.76 7 275606 43 42345679
Catarrh 14.67 10.76 77 275536 5909 42339813
Burns second degree 14.65 10.76 78 275535 6018 42339704
Transplant failure 14.64 10.76 4 275609 4040 42341682
Skin fissures 14.64 10.76 25 275588 9651 42336071
Hyperkalaemia 14.63 10.76 402 275211 80056 42265666
Dependent personality disorder 14.62 10.76 8 275605 70 42345652
Myoclonic epilepsy 14.61 10.76 33 275580 1641 42344081
Hepatocellular carcinoma 14.50 10.76 19 275594 8175 42337547
Leukopenia 14.50 10.76 370 275243 74376 42271346
Visual impairment 14.46 10.76 194 275419 42919 42302803
Analgesic drug level above therapeutic 14.43 10.76 14 275599 317 42345405
Trichoglossia 14.36 10.76 15 275598 372 42345350
Hallucination, visual 14.36 10.76 203 275410 20817 42324905
Nocturia 14.34 10.76 36 275577 12076 42333646
Sinus tachycardia 14.32 10.76 200 275413 20453 42325269
Cardiogenic shock 14.22 10.76 316 275297 35324 42310398
Right ventricle outflow tract obstruction 14.21 10.76 7 275606 48 42345674
Disturbance in attention 14.20 10.76 124 275489 29742 42315980
Systemic infection 14.17 10.76 8 275605 5197 42340525
Abdominal tenderness 14.16 10.76 65 275548 4724 42340998
Hypotensive crisis 14.15 10.76 8 275605 75 42345647
Blood testosterone decreased 14.13 10.76 7 275606 4895 42340827
Bronchopulmonary aspergillosis 14.12 10.76 71 275542 19358 42326364
Product storage error 14.07 10.76 32 275581 11108 42334614
Neurological symptom 14.05 10.76 27 275586 9964 42335758
Intervertebral discitis 14.05 10.76 48 275565 3042 42342680
Alcoholic coma 13.97 10.76 8 275605 77 42345645
Failure to suspend medication 13.89 10.76 15 275598 387 42345335
Hyperchloraemia 13.89 10.76 18 275595 566 42345156
Wound infection 13.84 10.76 97 275516 8249 42337473
Underdose 13.84 10.76 58 275555 16608 42329114
Stress 13.75 10.76 379 275234 43833 42301889
Clonus 13.72 10.76 52 275561 3468 42342254
Abdominal discomfort 13.68 10.76 376 275237 74879 42270843
Polyneuropathy 13.68 10.76 68 275545 18593 42327129
Salmonella bacteraemia 13.59 10.76 16 275597 455 42345267
Angina unstable 13.58 10.76 34 275579 11414 42334308
Lymphocyte count decreased 13.55 10.76 254 275359 27555 42318167
Transient ischaemic attack 13.54 10.76 146 275467 33593 42312129
Nodule 13.53 10.76 39 275574 12495 42333227
Renal failure 13.47 10.76 776 274837 142950 42202772
SARS-CoV-2 test negative 13.33 10.76 33 275580 1742 42343980
Aplasia pure red cell 13.33 10.76 16 275597 7150 42338572
Renal fusion anomaly 13.31 10.76 8 275605 85 42345637
Lipodystrophy acquired 13.29 10.76 3 275610 3447 42342275
Bezoar 13.26 10.76 27 275586 1249 42344473
Incorrect dose administered 13.23 10.76 442 275171 52532 42293190
Urethral valves 13.23 10.76 12 275601 249 42345473
Escherichia bacteraemia 13.15 10.76 67 275546 5082 42340640
Activated partial thromboplastin time prolonged 13.13 10.76 159 275454 15744 42329978
Granulocytopenia 13.11 10.76 16 275597 7098 42338624
Encephalopathy 13.05 10.76 355 275258 40978 42304744
Loss of personal independence in daily activities 13.03 10.76 235 275378 49581 42296141
Candida infection 12.99 10.76 84 275529 21526 42324196
Hepatic encephalopathy 12.97 10.76 163 275450 16279 42329443
Incorrect dosage administered 12.96 10.76 32 275581 1686 42344036
Erythema annulare 12.92 10.76 8 275605 90 42345632
Foreign body aspiration 12.89 10.76 13 275600 309 42345413
Multiple sclerosis relapse 12.89 10.76 48 275565 14216 42331506
Leukaemia 12.89 10.76 11 275602 5761 42339961
Myelodysplastic syndrome 12.88 10.76 90 275523 22655 42323067
Pemphigoid 12.88 10.76 35 275578 11432 42334290
Neuroblastoma 12.86 10.76 13 275600 310 42345412
Deep vein thrombosis 12.85 10.76 389 275224 76568 42269154
Haemolysis 12.85 10.76 106 275507 9483 42336239
Aspiration 12.73 10.76 174 275439 17712 42328010
Biliary ischaemia 12.70 10.76 8 275605 93 42345629
Red blood cell sedimentation rate decreased 12.69 10.76 12 275601 263 42345459
Prescribed overdose 12.69 10.76 42 275571 12885 42332837
Actinic keratosis 12.65 10.76 9 275604 5167 42340555
Diffuse large B-cell lymphoma recurrent 12.61 10.76 8 275605 4878 42340844
Gingival pain 12.53 10.76 96 275517 8398 42337324
Treatment noncompliance 12.46 10.76 170 275443 37502 42308220
Drug interaction 12.45 10.76 1524 274089 265475 42080247
Severe invasive streptococcal infection 12.45 10.76 6 275607 39 42345683
Endocardial fibrosis 12.32 10.76 5 275608 20 42345702
Hepatitis cholestatic 12.32 10.76 107 275506 9717 42336005
Injury 12.30 10.76 89 275524 22227 42323495
Respiratory syncytial virus bronchitis 12.27 10.76 8 275605 99 42345623
Insurance issue 12.27 10.76 56 275557 4060 42341662
Hypophosphataemia 12.26 10.76 197 275416 20748 42324974
Gastric cancer 12.22 10.76 16 275597 6887 42338835
Ejection fraction decreased 12.21 10.76 88 275525 21999 42323723
Congenital megacolon 12.17 10.76 7 275606 68 42345654
Wrong schedule 12.14 10.76 13 275600 332 42345390
Burn of internal organs 12.14 10.76 3 275610 0 42345722
Osteolysis 12.13 10.76 4 275609 3576 42342146
Oxygen saturation abnormal 12.11 10.76 34 275579 1937 42343785
Lymphocyte count 12.09 10.76 11 275602 229 42345493
Administration site erythema 12.09 10.76 7 275606 69 42345653
Delirium 12.06 10.76 434 275179 52085 42293637
Oropharyngeal pain 12.01 10.76 360 275253 42150 42303572
Type I hypersensitivity 11.99 10.76 36 275577 2130 42343592
Oral pruritus 11.99 10.76 16 275597 518 42345204
Cryptococcosis 11.96 10.76 3 275610 3208 42342514
Fear 11.92 10.76 34 275579 10931 42334791
Starvation ketoacidosis 11.91 10.76 9 275604 143 42345579
Arthropathy 11.91 10.76 128 275485 29469 42316253
Surgery 11.90 10.76 66 275547 17550 42328172
Device use error 11.88 10.76 3 275610 3194 42342528
Arthralgia 11.88 10.76 1154 274459 204084 42141638
White coat hypertension 11.87 10.76 13 275600 341 42345381
Metastatic lymphoma 11.87 10.76 14 275599 399 42345323
Unintentional medical device removal 11.85 10.76 3 275610 3188 42342534
Maple syrup disease 11.85 10.76 4 275609 8 42345714
Antacid therapy 11.78 10.76 61 275552 4656 42341066
Renal cancer 11.76 10.76 22 275591 8202 42337520
Increased appetite 11.73 10.76 25 275588 8881 42336841
Parkinsonism hyperpyrexia syndrome 11.72 10.76 13 275600 346 42345376
Immunosuppressant drug level increased 11.67 10.76 20 275593 7711 42338011
Major depression 11.59 10.76 67 275546 5331 42340391
Infusion site nodule 11.50 10.76 8 275605 111 42345611
Diabetes mellitus 11.50 10.76 298 275315 59789 42285933
Hand deformity 11.45 10.76 5 275608 3763 42341959
Drug screen positive 11.43 10.76 55 275558 4076 42341646
Epstein-Barr virus infection 11.42 10.76 29 275584 9689 42336033
Serum sickness 11.41 10.76 36 275577 2189 42343533
Therapeutic product effect variable 11.40 10.76 3 275610 3106 42342616
Blood immunoglobulin A decreased 11.39 10.76 18 275595 681 42345041
Carotid artery stenosis 11.37 10.76 11 275602 5425 42340297
Anal inflammation 11.37 10.76 36 275577 2193 42343529
Acid-base balance disorder mixed 11.31 10.76 6 275607 49 42345673
Hypertriglyceridaemia 11.30 10.76 31 275582 10095 42335627
Loss of consciousness 11.30 10.76 485 275128 91869 42253853
Circulatory collapse 11.29 10.76 98 275515 23538 42322184
Bacteraemia 11.28 10.76 226 275387 24814 42320908
Tension headache 11.24 10.76 4 275609 3410 42342312
Lymphadenopathy 11.24 10.76 150 275463 33215 42312507
Device issue 11.23 10.76 47 275566 13462 42332260
Polyneuropathy in malignant disease 11.23 10.76 13 275600 363 42345359
Platelet transfusion 11.18 10.76 30 275583 1664 42344058
Allergy test negative 11.16 10.76 9 275604 158 42345564
Urine bilirubin increased 11.14 10.76 7 275606 81 42345641
Porcelain gallbladder 11.13 10.76 5 275608 27 42345695
Metastases to liver 11.12 10.76 61 275552 16265 42329457
Steroid dependence 11.08 10.76 78 275535 6644 42339078
PCO2 decreased 11.07 10.76 31 275582 1763 42343959
Plasma cell myeloma 11.06 10.76 229 275384 47349 42298373
Libido decreased 11.04 10.76 10 275603 5088 42340634
Environmental exposure 11.03 10.76 11 275602 258 42345464
Coronary arterial stent insertion 11.03 10.76 6 275607 3979 42341743
Low density lipoprotein increased 11.02 10.76 11 275602 5344 42340378
Cytomegalovirus colitis 11.01 10.76 6 275607 3975 42341747
Allergic oedema 10.99 10.76 7 275606 83 42345639
Infusion site haemorrhage 10.95 10.76 25 275588 1252 42344470
Obesity 10.93 10.76 62 275551 16397 42329325
Teething 10.92 10.76 7 275606 84 42345638
Kidney transplant rejection 10.92 10.76 25 275588 8658 42337064
Dyspnoea at rest 10.91 10.76 7 275606 4242 42341480
Congenital multiplex arthrogryposis 10.89 10.76 11 275602 262 42345460
Anticoagulant therapy 10.88 10.76 58 275555 4477 42341245
Acute graft versus host disease in intestine 10.86 10.76 6 275607 3945 42341777
Gastric disorder 10.85 10.76 40 275573 11882 42333840
Anion gap increased 10.84 10.76 34 275579 2060 42343662
Parosmia 10.84 10.76 86 275527 7605 42338117
JC virus infection 10.82 10.76 3 275610 3001 42342721
Viral load increased 10.78 10.76 3 275610 2994 42342728
Hypocalcaemia 10.77 10.76 134 275479 30039 42315683
Medication overuse headache 10.77 10.76 10 275603 214 42345508

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 5225.47 10.14 12184 930816 468371 109177928
Completed suicide 4757.55 10.14 7885 935115 234496 109411803
Exposure to toxic agent 3013.51 10.14 1679 941321 11179 109635120
Intentional overdose 2354.03 10.14 4127 938873 128374 109517925
Acute hepatic failure 1430.58 10.14 1659 941341 34809 109611490
Overdose 1021.88 10.14 4326 938674 229468 109416831
Intentional product misuse 1014.95 10.14 2958 940042 129946 109516353
Hepatic cytolysis 995.48 10.14 1729 941271 53324 109592975
Infusion related reaction 967.88 10.14 6057 936943 375105 109271194
Suicide attempt 930.85 10.14 2444 940556 100950 109545349
Blood pressure fluctuation 781.82 10.14 1872 941128 72952 109573347
Poisoning deliberate 642.27 10.14 948 942052 25383 109620916
Metabolic acidosis 609.17 10.14 2055 940945 97689 109548610
Injection site pain 563.53 10.14 416 942584 177506 109468793
Analgesic drug level increased 560.42 10.14 374 942626 3572 109642727
Drug ineffective 447.33 10.14 9732 933268 1510808 108135491
Suspected suicide 443.08 10.14 596 942404 14603 109631696
Product dose omission issue 425.41 10.14 1367 941633 320415 109325884
Myelosuppression 404.43 10.14 149 942851 94191 109552108
Drug abuse 395.22 10.14 2730 940270 174681 109471618
Pyroglutamic acidosis 378.36 10.14 230 942770 1838 109644461
Medication error 376.48 10.14 1838 941162 103528 109542771
Rheumatoid arthritis 357.78 10.14 4019 938981 295594 109350705
Duodenal ulcer perforation 334.99 10.14 2628 940372 175072 109471227
Throat irritation 328.36 10.14 1105 941895 52447 109593852
Injection site erythema 326.61 10.14 199 942801 93977 109552322
Myocardial infarction 318.41 10.14 730 942270 191353 109454946
Folliculitis 315.24 10.14 2478 940522 165175 109481124
Anion gap 310.84 10.14 200 942800 1785 109644514
Helicobacter infection 308.98 10.14 2627 940373 179250 109467049
Diarrhoea 304.59 10.14 7398 935602 1132107 108514192
Cytokine release syndrome 290.65 10.14 1280 941720 69026 109577273
Depressed level of consciousness 286.61 10.14 1788 941212 110490 109535809
Muscle injury 283.01 10.14 2114 940886 138693 109507606
Heart rate decreased 282.41 10.14 1425 941575 81331 109564968
Anaemia 278.88 10.14 3151 939849 543935 109102364
Cardiac failure congestive 277.78 10.14 541 942459 150459 109495840
Lower respiratory tract infection 272.64 10.14 3222 939778 239884 109406415
Hepatotoxicity 268.74 10.14 1163 941837 62237 109584062
Coagulopathy 266.77 10.14 862 942138 40049 109606250
Irritable bowel syndrome 265.91 10.14 2347 940653 161868 109484431
Sinusitis 261.77 10.14 3763 939237 292925 109353374
Disease progression 260.81 10.14 1131 941869 242903 109403396
Sleep disorder due to general medical condition, insomnia type 257.67 10.14 1663 941337 103980 109542319
Hepatic enzyme increased 256.30 10.14 4001 938999 316891 109329408
Anti-cyclic citrullinated peptide antibody positive 252.66 10.14 2517 940483 179467 109466832
Intentional product use issue 251.79 10.14 3225 939775 244681 109401618
Hand deformity 248.10 10.14 2903 940097 215603 109430696
Drug resistance 238.33 10.14 91 942909 56283 109590016
Pericarditis 235.58 10.14 2881 940119 216233 109430066
Pemphigus 235.37 10.14 2832 940168 211738 109434561
Wrong technique in product usage process 234.29 10.14 239 942761 87109 109559190
Poisoning 228.93 10.14 655 942345 28450 109617849
Ill-defined disorder 227.28 10.14 2189 940811 154664 109491635
Liver injury 223.83 10.14 2111 940889 148302 109497997
Cardiac failure 220.29 10.14 838 942162 186788 109459511
Blood pressure increased 214.50 10.14 3243 939757 255130 109391169
Renal impairment 212.09 10.14 856 942144 187589 109458710
Nasopharyngitis 210.12 10.14 4617 938383 389744 109256555
Glossodynia 209.97 10.14 2851 940149 219153 109427146
Device expulsion 208.36 10.14 14 942986 30877 109615422
Blood pressure systolic increased 203.34 10.14 1308 941692 81683 109564616
Blister 202.91 10.14 2890 940110 224486 109421813
Wound 201.00 10.14 2959 940041 231478 109414821
Accidental overdose 200.97 10.14 926 942074 50908 109595391
Blood pressure diastolic abnormal 199.22 10.14 577 942423 25238 109621061
Blood pressure systolic abnormal 198.14 10.14 562 942438 24288 109622011
Cardio-respiratory arrest 197.64 10.14 1675 941325 114161 109532138
Malignant neoplasm progression 196.42 10.14 793 942207 173774 109472525
Impaired healing 194.60 10.14 2547 940453 194170 109452129
Systemic lupus erythematosus 192.76 10.14 3144 939856 251194 109395105
Injection site swelling 188.51 10.14 150 942850 61640 109584659
Ear pruritus 188.11 10.14 269 942731 6991 109639308
Injection site pruritus 185.26 10.14 103 942897 51155 109595144
Pancytopenia 169.16 10.14 1069 941931 208544 109437755
Coma 164.87 10.14 1633 941367 116236 109530063
Discomfort 163.37 10.14 2656 940344 212051 109434248
Respiratory arrest 161.19 10.14 948 942052 57351 109588948
Neutropenia 159.86 10.14 2240 940760 372380 109273919
Synovitis 158.84 10.14 3249 939751 270843 109375456
Injection site bruising 158.21 10.14 123 942877 51140 109595159
Blood pressure diastolic decreased 158.03 10.14 666 942334 35219 109611080
Prothrombin time ratio decreased 157.28 10.14 121 942879 1471 109644828
Rheumatic fever 154.24 10.14 1662 941338 120917 109525382
Oxygen saturation decreased 152.09 10.14 2025 940975 154957 109491342
Dry skin 143.73 10.14 455 942545 107198 109539101
Gastrointestinal disorder 138.19 10.14 2862 940138 239090 109407209
Hepatic necrosis 137.34 10.14 278 942722 9644 109636655
Dehydration 136.68 10.14 1624 941376 277887 109368412
Body temperature increased 134.43 10.14 863 942137 53850 109592449
Osteonecrosis of jaw 132.65 10.14 128 942872 47889 109598410
Respiratory depression 131.77 10.14 582 942418 31419 109614880
Therapy interrupted 130.58 10.14 139 942861 49683 109596616
Bone marrow failure 128.87 10.14 183 942817 57665 109588634
Therapy cessation 126.94 10.14 117 942883 44740 109601559
Drug interaction 126.33 10.14 3272 939728 496911 109149388
Hypersensitivity 124.82 10.14 4411 938589 399587 109246712
White blood cell count decreased 123.91 10.14 1303 941697 228087 109418212
Neuropathy peripheral 123.18 10.14 958 942042 178319 109467980
Hepatic failure 119.36 10.14 998 942002 67741 109578558
Joint swelling 118.57 10.14 4759 938241 438086 109208213
Weight increased 118.53 10.14 4536 938464 415108 109231191
Arthropathy 117.84 10.14 3249 939751 284273 109362026
Methaemoglobinaemia 117.66 10.14 249 942751 8919 109637380
Atrial fibrillation 116.62 10.14 1323 941677 228319 109417980
Neoplasm progression 116.54 10.14 234 942766 64361 109581938
Hepatitis fulminant 116.31 10.14 238 942762 8322 109637977
Sedation complication 112.38 10.14 399 942601 19456 109626843
Pharyngeal paraesthesia 111.35 10.14 156 942844 3976 109642323
Feeling abnormal 111.32 10.14 994 942006 179717 109466582
Coronary artery disease 111.18 10.14 282 942718 71408 109574891
Dyspnoea exertional 110.05 10.14 484 942516 103576 109542723
Hepatitis acute 109.57 10.14 381 942619 18385 109627914
Full blood count abnormal 108.18 10.14 195 942805 55857 109590442
Renal failure 106.35 10.14 1328 941672 225246 109421053
Swelling 105.99 10.14 3823 939177 347218 109299081
Gastrointestinal haemorrhage 104.79 10.14 904 942096 164614 109481685
Exposure via ingestion 103.41 10.14 165 942835 4735 109641564
Mobility decreased 102.73 10.14 2702 940298 234720 109411579
Hospitalisation 100.91 10.14 755 942245 141738 109504561
Sopor 100.28 10.14 98 942902 36448 109609851
Dyspnoea 99.76 10.14 8106 934894 1098766 108547533
Swollen joint count increased 96.42 10.14 1115 941885 82546 109563753
Platelet count decreased 96.07 10.14 1384 941616 229059 109417240
Cerebrovascular accident 95.76 10.14 1035 941965 180249 109466050
Dermatitis atopic 95.71 10.14 49 942951 25492 109620807
Acute myocardial infarction 95.20 10.14 379 942621 83398 109562901
Injection site warmth 94.59 10.14 17 942983 17388 109628911
Interstitial lung disease 94.56 10.14 747 942253 138587 109507712
Creatinine renal clearance decreased 93.83 10.14 402 942598 21413 109624886
Cerebral infarction 93.33 10.14 188 942812 51650 109594649
Syncope 92.85 10.14 1193 941807 201343 109444956
Injection site haemorrhage 92.45 10.14 87 942913 32941 109613358
Injection site rash 90.68 10.14 43 942957 23376 109622923
Leukopenia 90.07 10.14 822 942178 147969 109498330
Post transplant lymphoproliferative disorder 89.90 10.14 13 942987 15600 109630699
Unevaluable event 89.52 10.14 236 942764 58991 109587308
Heart rate irregular 89.42 10.14 549 942451 33725 109612574
Confusional state 89.00 10.14 4867 938133 463813 109182486
Rheumatoid factor positive 88.67 10.14 1597 941403 130043 109516256
Facet joint syndrome 88.42 10.14 1236 941764 95592 109550707
Product prescribing error 88.35 10.14 191 942809 51140 109595159
Myalgia 87.72 10.14 1350 941650 221031 109425268
Hyperkalaemia 87.15 10.14 739 942261 135057 109511242
Device difficult to use 87.06 10.14 26 942974 18779 109627520
Prostate cancer 86.93 10.14 116 942884 37525 109608774
Product substitution issue 86.78 10.14 44 942956 23017 109623282
Heart rate increased 86.59 10.14 1715 941285 142119 109504180
Cytomegalovirus infection 86.11 10.14 212 942788 54232 109592067
Drug-induced liver injury 86.02 10.14 1471 941529 118596 109527703
Transient ischaemic attack 85.69 10.14 270 942730 63712 109582587
Therapeutic product effect incomplete 85.46 10.14 1367 941633 222438 109423861
Visual acuity reduced 85.17 10.14 89 942911 32084 109614215
Urticaria 85.14 10.14 3426 939574 315431 109330868
Injection site urticaria 84.97 10.14 21 942979 17194 109629105
Pathogen resistance 84.47 10.14 23 942977 17649 109628650
Device issue 84.36 10.14 102 942898 34433 109611866
Cerebral haemorrhage 83.65 10.14 279 942721 64689 109581610
Forced expiratory volume decreased 83.22 10.14 8 942992 13168 109633131
Blood pressure diastolic increased 82.77 10.14 349 942651 18458 109627841
Lip dry 82.10 10.14 1254 941746 98829 109547470
Bursitis 81.91 10.14 1560 941440 128358 109517941
Fixed eruption 81.86 10.14 137 942863 4095 109642204
Drug dose omission by device 81.49 10.14 13 942987 14503 109631796
Surgery 81.13 10.14 142 942858 41141 109605158
Multiple-drug resistance 81.10 10.14 9 942991 13226 109633073
Joint range of motion decreased 79.25 10.14 1470 941530 120362 109525937
Thrombotic microangiopathy 79.02 10.14 79 942921 29070 109617229
Septic shock 78.99 10.14 910 942090 156618 109489681
Red blood cell sedimentation rate abnormal 77.95 10.14 57 942943 24452 109621847
Body temperature decreased 77.85 10.14 561 942439 36374 109609925
Hypocalcaemia 77.29 10.14 291 942709 65075 109581224
Stomatitis 77.15 10.14 2925 940075 267317 109378982
Fibromyalgia 76.80 10.14 1955 941045 168954 109477345
Haematotoxicity 76.71 10.14 42 942958 21040 109625259
Diabetes mellitus 76.00 10.14 515 942485 98866 109547433
Myelodysplastic syndrome 75.43 10.14 127 942873 37357 109608942
Injury 75.39 10.14 2013 940987 175252 109471047
Diabetic ketoacidosis 75.32 10.14 153 942847 41905 109604394
Seizure 74.76 10.14 1381 941619 219804 109426495
Injection site mass 74.76 10.14 60 942940 24553 109621746
Blood glucose increased 73.82 10.14 747 942253 131749 109514550
Anion gap abnormal 72.82 10.14 59 942941 777 109645522
Product storage error 72.46 10.14 48 942952 21680 109624619
Acute lung injury 71.92 10.14 110 942890 3041 109643258
Posterior reversible encephalopathy syndrome 71.64 10.14 111 942889 33750 109612549
Infusion site pruritus 71.33 10.14 142 942858 4866 109641433
Respiratory failure 70.75 10.14 1351 941649 213981 109432318
Hypothyroidism 70.04 10.14 351 942649 72548 109573751
Pyroglutamate increased 69.96 10.14 52 942948 598 109645701
Acute myeloid leukaemia 69.65 10.14 137 942863 37973 109608326
Contusion 69.30 10.14 2537 940463 230824 109415475
Muscle spasticity 69.18 10.14 534 942466 35381 109610918
Aspergillus infection 68.78 10.14 70 942930 25546 109620753
Vision blurred 68.78 10.14 735 942265 128287 109518012
Device malfunction 68.45 10.14 70 942930 25488 109620811
Transplant rejection 68.43 10.14 65 942935 24502 109621797
Osteonecrosis 68.19 10.14 114 942886 33627 109612672
Thrombocytopenia 67.96 10.14 2363 940637 346522 109299777
Palmar-plantar erythrodysaesthesia syndrome 67.86 10.14 156 942844 40869 109605430
Clostridium test positive 67.85 10.14 226 942774 10667 109635632
Oesophageal carcinoma 67.76 10.14 9 942991 11515 109634784
Deep vein thrombosis 67.47 10.14 815 942185 139072 109507227
Decreased appetite 67.44 10.14 3342 939658 472504 109173795
Blood cholesterol increased 67.12 10.14 2057 940943 182728 109463571
Dizziness 66.92 10.14 5086 937914 693107 108953192
Cross sensitivity reaction 66.63 10.14 147 942853 5420 109640879
Type 2 diabetes mellitus 66.01 10.14 1979 941021 175253 109471046
Blood calcium decreased 65.76 10.14 527 942473 35318 109610981
Inspiratory capacity decreased 65.55 10.14 95 942905 2500 109643799
Cytopenia 65.38 10.14 97 942903 30019 109616280
Bladder cancer 64.78 10.14 47 942953 20245 109626054
Poor venous access 64.73 10.14 394 942606 24128 109622171
Night sweats 64.49 10.14 1547 941453 132436 109513863
Second primary malignancy 64.30 10.14 37 942963 18031 109628268
Contraindicated product administered 64.28 10.14 2659 940341 245608 109400691
Acute kidney injury 64.05 10.14 4609 938391 630821 109015478
Drug use disorder 63.60 10.14 314 942686 17760 109628539
Epistaxis 63.48 10.14 758 942242 129614 109516685
Loss of consciousness 63.16 10.14 1236 941764 195070 109451229
Pulmonary alveolar haemorrhage 62.62 10.14 48 942952 20102 109626197
Immune reconstitution inflammatory syndrome 62.51 10.14 30 942970 16196 109630103
Haemorrhage 61.74 10.14 596 942404 106096 109540203
Psoriasis 61.08 10.14 833 942167 139160 109507139
Graft versus host disease 60.77 10.14 43 942957 18763 109627536
Therapeutic product effect decreased 60.61 10.14 2605 940395 241711 109404588
Drug ineffective for unapproved indication 60.56 10.14 572 942428 102266 109544033
Electrocardiogram QT prolonged 60.41 10.14 615 942385 108345 109537954
Infusion site erythema 59.87 10.14 231 942769 11728 109634571
Fall 59.73 10.14 4384 938616 599098 109047201
Deep vein thrombosis postoperative 59.55 10.14 770 942230 58521 109587778
Device use error 58.80 10.14 5 942995 9084 109637215
Unintentional medical device removal 57.48 10.14 5 942995 8918 109637381
Hypocoagulable state 56.49 10.14 89 942911 2526 109643773
Generalised bullous fixed drug eruption 56.20 10.14 50 942950 754 109645545
BK virus infection 55.65 10.14 21 942979 13085 109633214
Cytomegalovirus viraemia 55.61 10.14 42 942958 17722 109628577
Pulmonary hypertension 55.30 10.14 262 942738 54958 109591341
Sedation 54.82 10.14 867 942133 68816 109577483
Ventricular tachycardia 54.46 10.14 230 942770 49779 109596520
Sciatica 54.02 10.14 1097 941903 91302 109554997
Polyneuropathy 53.54 10.14 121 942879 31891 109614408
Somnolence 52.53 10.14 3069 939931 294380 109351919
Wound infection 52.40 10.14 1133 941867 95332 109550967
Respiratory rate increased 52.30 10.14 380 942620 24703 109621596
Inappropriate schedule of product administration 52.25 10.14 2179 940821 201458 109444841
Injection site induration 52.22 10.14 16 942984 11367 109634932
Infusion site pain 51.91 10.14 289 942711 17130 109629169
Cardiac disorder 51.72 10.14 409 942591 75871 109570428
Hepatic encephalopathy 51.60 10.14 415 942585 27841 109618458
Mixed liver injury 51.49 10.14 222 942778 11857 109634442
Prothrombin time shortened 51.47 10.14 103 942897 3543 109642756
Hypomagnesaemia 51.21 10.14 303 942697 60067 109586232
Tachycardia 50.84 10.14 2392 940608 224253 109422046
Therapy partial responder 50.62 10.14 155 942845 36906 109609393
Metastases to liver 50.49 10.14 145 942855 35241 109611058
Hypomania 50.12 10.14 196 942804 10014 109636285
Spinal stenosis 50.12 10.14 53 942947 19003 109627296
Vomiting 50.09 10.14 8660 934340 902015 108744284
Pneumocystis jirovecii pneumonia 50.04 10.14 191 942809 42544 109603755
Abortion spontaneous 50.01 10.14 139 942861 34143 109612156
Sepsis 49.92 10.14 2281 940719 325065 109321234
Chronic graft versus host disease 49.77 10.14 10 942990 9447 109636852
Infusion site swelling 49.62 10.14 191 942809 9686 109636613
Acute graft versus host disease 49.34 10.14 24 942976 12857 109633442
Electric shock 49.24 10.14 69 942931 1759 109644540
Full blood count decreased 49.20 10.14 127 942873 31972 109614327
Mucosal inflammation 49.12 10.14 553 942447 95588 109550711
Thrombosis 49.06 10.14 642 942358 108020 109538279
Device leakage 48.89 10.14 39 942961 16009 109630290
Schizophrenia 48.62 10.14 336 942664 21490 109624809
Obstructive airways disorder 48.57 10.14 215 942785 45934 109600365
Chronic kidney disease 48.57 10.14 416 942584 75875 109570424
COVID-19 48.47 10.14 2555 940445 242505 109403794
Systemic infection 48.42 10.14 12 942988 9807 109636492
Hypotension 47.88 10.14 5135 937865 518714 109127585
Therapeutic response decreased 47.76 10.14 559 942441 95940 109550359
Acute graft versus host disease in skin 47.67 10.14 16 942984 10724 109635575
Basal cell carcinoma 47.59 10.14 211 942789 45059 109601240
Autoimmune disorder 47.52 10.14 804 942196 64679 109581620
Disease recurrence 47.46 10.14 313 942687 60471 109585828
Bronchopulmonary aspergillosis 47.45 10.14 116 942884 29747 109616552
Gait disturbance 47.33 10.14 1915 941085 276293 109370006
Sudden infant death syndrome 46.98 10.14 32 942968 317 109645982
Cardiac failure chronic 46.75 10.14 30 942970 13781 109632518
Infusion site extravasation 46.70 10.14 210 942790 11424 109634875
Device dislocation 46.65 10.14 128 942872 31576 109614723
Multiple sclerosis relapse 46.51 10.14 245 942755 49995 109596304
Ear pain 46.41 10.14 674 942326 52552 109593747
Mydriasis 46.39 10.14 336 942664 21821 109624478
Intercepted product preparation error 46.26 10.14 3 942997 6817 109639482
Staphylococcal infection 46.06 10.14 378 942622 69566 109576733
White blood cells urine positive 45.89 10.14 155 942845 7369 109638930
Eosinophilic granulomatosis with polyangiitis 45.58 10.14 17 942983 10669 109635630
Skin exfoliation 45.24 10.14 503 942497 87148 109559151
Crystal urine present 45.18 10.14 69 942931 1905 109644394
Neutrophil percentage increased 45.06 10.14 117 942883 4796 109641503
Inflammation 44.96 10.14 2047 940953 191191 109455108
Renal disorder 44.86 10.14 243 942757 49236 109597063
Neurotoxicity 44.80 10.14 196 942804 42011 109604288
Angina unstable 44.01 10.14 45 942955 16387 109629912
Coeliac disease 43.85 10.14 562 942438 42625 109603674
Product monitoring error 43.84 10.14 11 942989 8916 109637383
Bone pain 43.81 10.14 350 942650 64783 109581516
Injection site reaction 43.69 10.14 517 942483 88553 109557746
Nocardiosis 43.65 10.14 6 942994 7480 109638819
Weight fluctuation 43.06 10.14 330 942670 21815 109624484
Lymphadenopathy 42.94 10.14 343 942657 63492 109582807
Serotonin syndrome 42.82 10.14 726 942274 58427 109587872
Toxic epidermal necrolysis 42.82 10.14 701 942299 56026 109590273
Jaundice cholestatic 42.63 10.14 241 942759 14367 109631932
Labelled drug-drug interaction medication error 42.60 10.14 119 942881 29183 109617116
Haematuria 42.58 10.14 477 942523 82528 109563771
Product dose omission in error 42.56 10.14 85 942915 23427 109622872
Pulmonary arterial hypertension 42.52 10.14 139 942861 32429 109613870
Breast cancer female 42.31 10.14 27 942973 12441 109633858
Musculoskeletal stiffness 42.02 10.14 2847 940153 276975 109369324
Epstein-Barr virus infection 42.01 10.14 59 942941 18679 109627620
Urinary tract infection 41.93 10.14 2314 940686 323968 109322331
Oedema peripheral 41.66 10.14 2334 940666 326326 109319973
Dry mouth 41.63 10.14 2095 940905 197853 109448446
Substance abuse 41.37 10.14 213 942787 12250 109634049
Peripheral venous disease 41.31 10.14 974 942026 83143 109563156
Myopathy 41.21 10.14 95 942905 24865 109621434
Treatment noncompliance 40.86 10.14 411 942589 72579 109573720
Asthenia 40.86 10.14 5198 937802 683801 108962498
Cystitis haemorrhagic 40.67 10.14 27 942973 12182 109634117
Haemoglobin decreased 40.41 10.14 1721 941279 247006 109399293
Endophthalmitis 40.38 10.14 10 942990 8177 109638122
Alanine aminotransferase increased 40.24 10.14 1935 941065 181838 109464461
Urine abnormality 40.19 10.14 169 942831 8927 109637372
Blood potassium decreased 40.09 10.14 283 942717 53831 109592468
Pulmonary embolism 40.05 10.14 1460 941540 213014 109433285
Gastric cancer 39.95 10.14 22 942978 10986 109635313
Cardiac failure acute 39.47 10.14 92 942908 23986 109622313
Renal cortical necrosis 39.47 10.14 34 942966 490 109645809
Mycotic allergy 39.29 10.14 3 942997 5951 109640348
Medication overuse headache 39.16 10.14 57 942943 1506 109644793
Oral pruritus 38.99 10.14 87 942913 3233 109643066
Loss of personal independence in daily activities 38.95 10.14 977 942023 149043 109497256
Haematochezia 38.79 10.14 722 942278 114802 109531497
Right ventricular failure 38.78 10.14 104 942896 25850 109620449
Graft versus host disease in gastrointestinal tract 38.70 10.14 14 942986 8954 109637345
Neuritis 38.57 10.14 8 942992 7391 109638908
Incorrect dose administered by device 38.48 10.14 6 942994 6808 109639491
Sleep disorder due to a general medical condition 38.38 10.14 273 942727 51839 109594460
Venoocclusive liver disease 38.12 10.14 44 942956 15163 109631136
Brain death 37.98 10.14 133 942867 6440 109639859
Breast cancer 37.93 10.14 184 942816 38358 109607941
Body temperature fluctuation 37.89 10.14 93 942907 3680 109642619
Product use in unapproved indication 37.88 10.14 3291 939709 444086 109202213
Anticipatory anxiety 37.75 10.14 50 942950 1206 109645093
Febrile neutropenia 37.69 10.14 3164 939836 313603 109332696
Renal papillary necrosis 37.67 10.14 31 942969 418 109645881
No adverse event 37.61 10.14 425 942575 73414 109572885
Hypercalcaemia 37.07 10.14 239 942761 46418 109599881
Dermatitis 36.90 10.14 118 942882 27719 109618580
Live birth 36.75 10.14 813 942187 68671 109577628
Neuroblastoma recurrent 36.60 10.14 33 942967 507 109645792
Glycosylated haemoglobin increased 36.55 10.14 93 942907 23526 109622773
Lymphocyte percentage decreased 36.55 10.14 114 942886 5196 109641103
Acidosis 36.42 10.14 322 942678 22209 109624090
Anion gap increased 36.36 10.14 100 942900 4244 109642055
Neutrophil count decreased 36.35 10.14 770 942230 120171 109526128
Product preparation error 36.32 10.14 24 942976 10855 109635444
Analgesic drug level above therapeutic 36.27 10.14 32 942968 477 109645822
Complication of device insertion 36.15 10.14 15 942985 8823 109637476
Therapeutic response unexpected 36.04 10.14 95 942905 23748 109622551
Dyskinesia 35.74 10.14 274 942726 51172 109595127
Grip strength decreased 35.67 10.14 916 942084 79258 109567041
Sexual dysfunction 35.67 10.14 14 942986 8516 109637783
Hypothermia 35.60 10.14 362 942638 25940 109620359
Drug withdrawal syndrome 35.55 10.14 185 942815 37869 109608430
Erectile dysfunction 35.41 10.14 65 942935 18491 109627808
Cardiomyopathy 35.39 10.14 156 942844 33369 109612930
Plasma cell myeloma 35.39 10.14 354 942646 62582 109583717
Pain in extremity 35.32 10.14 3625 939375 483493 109162806
Exposure via skin contact 35.22 10.14 36 942964 13111 109633188
Cognitive disorder 34.99 10.14 986 942014 86525 109559774
Hepatic function abnormal 34.87 10.14 543 942457 88752 109557547
Injection site discolouration 34.81 10.14 17 942983 9086 109637213
Hyperlipidaemia 34.78 10.14 172 942828 35676 109610623
Osteomyelitis 34.72 10.14 177 942823 36423 109609876
Toxicologic test abnormal 34.71 10.14 49 942951 1258 109645041
Mitral valve incompetence 34.64 10.14 156 942844 33173 109613126
Breast cancer stage I 34.59 10.14 10 942990 7377 109638922
Urine leukocyte esterase positive 34.56 10.14 90 942910 3696 109642603
Drug intolerance 34.26 10.14 3964 939036 402548 109243751
Specific gravity urine decreased 34.22 10.14 40 942960 846 109645453
Abdominal discomfort 34.19 10.14 3848 939152 390010 109256289
Breast cancer stage III 34.06 10.14 900 942100 78217 109568082
Coronary arterial stent insertion 33.88 10.14 5 942995 5910 109640389
Hypokalaemia 33.83 10.14 1243 941757 181205 109465094
Suicidal ideation 33.78 10.14 580 942420 93357 109552942
Finger deformity 33.75 10.14 431 942569 32661 109613638
Product label confusion 33.57 10.14 318 942682 22359 109623940
Torsade de pointes 33.44 10.14 91 942909 22509 109623790
Orthostatic hypotension 33.42 10.14 770 942230 65479 109580820
Cytomegalovirus infection reactivation 33.42 10.14 66 942934 18267 109628032
Red blood cell sedimentation rate 33.37 10.14 3 942997 5211 109641088
Acute respiratory failure 33.12 10.14 447 942553 74813 109571486
Diplopia 33.08 10.14 215 942785 41679 109604620
Asphyxia 32.96 10.14 221 942779 13994 109632305
Pneumonia 32.91 10.14 6788 936212 869926 108776373
Immunosuppressant drug level increased 32.68 10.14 31 942969 11693 109634606
Metastases to lung 32.54 10.14 95 942905 22968 109623331
Hypertensive crisis 32.53 10.14 103 942897 24269 109622030
Enthesopathy 32.49 10.14 35 942965 12443 109633856
Pulmonary vasculitis 32.38 10.14 8 942992 6552 109639747
Melaena 32.23 10.14 403 942597 68354 109577945
Graft versus host disease in skin 32.20 10.14 15 942985 8239 109638060
Accidental death 32.16 10.14 105 942895 4904 109641395
Status epilepticus 32.08 10.14 149 942851 31422 109614877
Blood pH decreased 31.91 10.14 100 942900 4569 109641730
Skin toxicity 31.86 10.14 32 942968 11751 109634548
Needle issue 31.86 10.14 65 942935 17775 109628524
Syringe issue 31.82 10.14 21 942979 9504 109636795
Hepatitis B reactivation 31.77 10.14 12 942988 7472 109638827
Pain in jaw 31.71 10.14 281 942719 50896 109595403
Lymphoproliferative disorder 31.61 10.14 11 942989 7207 109639092
Alopecia 31.57 10.14 3563 939437 361190 109285109
Carotid artery stenosis 31.52 10.14 20 942980 9243 109637056
Cerebral ischaemia 31.46 10.14 34 942966 12070 109634229
JC virus infection 31.42 10.14 4 942996 5286 109641013
Hepatocellular carcinoma 31.39 10.14 23 942977 9857 109636442
Candida infection 31.36 10.14 260 942740 47749 109598550
Hypertriglyceridaemia 31.35 10.14 56 942944 16098 109630201
Product complaint 31.31 10.14 44 942956 13928 109632371
Blood triglycerides increased 31.31 10.14 102 942898 23824 109622475
Renal cancer 31.30 10.14 39 942961 12995 109633304
Tardive dyskinesia 31.20 10.14 42 942958 13537 109632762
Dissociation 31.15 10.14 23 942977 9819 109636480
Mucormycosis 30.93 10.14 27 942973 10601 109635698
Multiple drug therapy 30.93 10.14 143 942857 7871 109638428
Tendonitis 30.91 10.14 116 942884 25967 109620332
Infusion site mass 30.87 10.14 54 942946 1674 109644625
Depression 30.73 10.14 2309 940691 315026 109331273
Disturbance in attention 30.73 10.14 359 942641 61636 109584663
Skin ulcer 30.61 10.14 371 942629 63274 109583025
Colorectal cancer 30.57 10.14 20 942980 9094 109637205
Urinary sediment present 30.54 10.14 67 942933 2461 109643838
Prostatic specific antigen increased 30.50 10.14 37 942963 12474 109633825
Bundle branch block left 30.50 10.14 39 942961 12849 109633450
Metastases to bone 30.16 10.14 151 942849 31221 109615078
Left ventricular dysfunction 30.16 10.14 101 942899 23392 109622907
Accidental poisoning 30.14 10.14 66 942934 2421 109643878
Personality disorder 30.02 10.14 200 942800 12637 109633662
Accidental exposure to product 29.93 10.14 277 942723 49731 109596568
Pleural effusion 29.83 10.14 1225 941775 176484 109469815
Delusion of grandeur 29.72 10.14 62 942938 2198 109644101
Transplant dysfunction 29.71 10.14 17 942983 8311 109637988
Hyponatraemia 29.56 10.14 1535 941465 216118 109430181
Blood parathyroid hormone decreased 29.55 10.14 41 942959 13048 109633251
Eczema 29.46 10.14 436 942564 71857 109574442
Adjustment disorder with depressed mood 29.40 10.14 532 942468 43351 109602948
Skin necrosis 29.35 10.14 90 942910 21422 109624877
Transaminases increased 29.31 10.14 728 942272 62662 109583637
Skin burning sensation 29.29 10.14 92 942908 21733 109624566
C-reactive protein 29.24 10.14 391 942609 29940 109616359
Accidental exposure to product by child 29.17 10.14 76 942924 3122 109643177
Circulatory collapse 28.92 10.14 231 942769 42762 109603537
Abnormal dreams 28.89 10.14 40 942960 12740 109633559
Intraocular pressure increased 28.88 10.14 30 942970 10846 109635453
Bezoar 28.80 10.14 88 942912 3966 109642333
Hepatitis C 28.78 10.14 39 942961 12534 109633765
Intervertebral discitis 28.68 10.14 127 942873 6863 109639436
Kidney transplant rejection 28.65 10.14 36 942964 11951 109634348
Ankylosing spondylitis 28.64 10.14 56 942944 15556 109630743
Genital haemorrhage 28.57 10.14 13 942987 7239 109639060
Sensitivity to weather change 28.56 10.14 26 942974 10002 109636297
Granulocytopenia 28.54 10.14 40 942960 12675 109633624
Actinic keratosis 28.53 10.14 12 942988 7001 109639298
Ductus arteriosus stenosis foetal 28.41 10.14 16 942984 109 109646190
Pneumatosis intestinalis 28.23 10.14 19 942981 8510 109637789
Rash pruritic 28.13 10.14 629 942371 97440 109548859
Thinking abnormal 28.04 10.14 54 942946 15086 109631213
Infective pulmonary exacerbation of cystic fibrosis 27.95 10.14 52 942948 14719 109631580
SARS-CoV-2 test positive 27.88 10.14 243 942757 16692 109629607
Ageusia 27.66 10.14 81 942919 19564 109626735
Pancreatic carcinoma 27.58 10.14 53 942947 14819 109631480
Alpha tumour necrosis factor increased 27.57 10.14 25 942975 387 109645912
Neurologic neglect syndrome 27.53 10.14 154 942846 9144 109637155
Polyomavirus-associated nephropathy 27.50 10.14 18 942982 8183 109638116
Varicella zoster virus infection 27.38 10.14 10 942990 6358 109639941
Subdural haematoma 27.32 10.14 190 942810 36264 109610035
Onychomadesis 27.31 10.14 544 942456 45119 109601180
X-ray abnormal 27.29 10.14 467 942533 37650 109608649
Tricuspid valve incompetence 27.11 10.14 108 942892 23765 109622534
Appendicolith 26.93 10.14 211 942789 14044 109632255
Brain oedema 26.80 10.14 393 942607 30705 109615594
Retinal haemorrhage 26.62 10.14 25 942975 9476 109636823
Cardiotoxicity 26.48 10.14 66 942934 16815 109629484
Visual impairment 26.48 10.14 909 942091 133519 109512780
Hypertension 26.48 10.14 4837 938163 505247 109141052
Nausea 26.45 10.14 9803 933197 1225887 108420412
Incorrect drug administration rate 26.44 10.14 105 942895 5403 109640896
Tremor 26.38 10.14 1432 941568 200800 109445499
Cholestasis 26.37 10.14 729 942271 63789 109582510
Speech disorder 26.26 10.14 368 942632 61201 109585098
Complication of device removal 26.25 10.14 4 942996 4616 109641683
Cytomegalovirus chorioretinitis 26.23 10.14 14 942986 7114 109639185
Respiratory symptom 26.22 10.14 55 942945 14890 109631409
Intestinal haemorrhage 26.17 10.14 15 942985 7326 109638973
Angioedema 26.16 10.14 1058 941942 97442 109548857
Adenocarcinoma of colon 26.00 10.14 10 942990 6158 109640141
Acute coronary syndrome 25.97 10.14 105 942895 23007 109623292
Dislocation of vertebra 25.86 10.14 520 942480 43201 109603098
Aplastic anaemia 25.82 10.14 319 942681 23989 109622310
Onychomycosis 25.77 10.14 467 942533 38064 109608235
Osmolar gap 25.68 10.14 17 942983 160 109646139
Vaginal haemorrhage 25.67 10.14 118 942882 24956 109621343
Blood immunoglobulin E increased 25.67 10.14 16 942984 7466 109638833
Product use issue 25.65 10.14 3035 939965 308660 109337639
Bilirubin urine present 25.60 10.14 22 942978 316 109645983
Aggression 25.57 10.14 353 942647 58857 109587442
Paraesthesia ear 25.57 10.14 27 942973 508 109645791
Maternal exposure during pregnancy 25.46 10.14 2514 940486 252369 109393930
Oropharyngeal discomfort 25.43 10.14 163 942837 10164 109636135
Complications of transplanted kidney 25.42 10.14 16 942984 7426 109638873
Squamous cell carcinoma 25.37 10.14 77 942923 18386 109627913
Arrhythmia 25.21 10.14 429 942571 69146 109577153
Aortic valve incompetence 25.19 10.14 34 942966 10947 109635352
Enterococcal infection 25.17 10.14 89 942911 20277 109626022
Vascular stent thrombosis 25.07 10.14 3 942997 4158 109642141
Conjunctivitis allergic 24.94 10.14 14 942986 6917 109639382
Pericardial effusion 24.75 10.14 341 942659 56876 109589423
Ascites 24.74 10.14 602 942398 92206 109554093
Proteinuria 24.68 10.14 220 942780 39798 109606501
Hypervolaemia 24.67 10.14 286 942714 49174 109597125
Self-medication 24.65 10.14 112 942888 6120 109640179
Delirium 24.55 10.14 1397 941603 133628 109512671
Low density lipoprotein increased 24.50 10.14 33 942967 10633 109635666
Congestive cardiomyopathy 24.39 10.14 53 942947 14166 109632133
Cytomegalovirus colitis 24.36 10.14 15 942985 7046 109639253
Sleep disorder 24.23 10.14 1988 941012 196656 109449643
Human herpesvirus 6 infection 24.11 10.14 13 942987 6568 109639731
Tachyarrhythmia 24.03 10.14 21 942979 8240 109638059
Fracture 24.01 10.14 119 942881 24669 109621630
Carpal tunnel syndrome 24.00 10.14 105 942895 22505 109623794
Monocyte chemotactic protein-1 increased 23.98 10.14 22 942978 346 109645953
C-reactive protein abnormal 23.80 10.14 1343 941657 128352 109517947
Infusion site rash 23.79 10.14 58 942942 2285 109644014
Maternal exposure timing unspecified 23.73 10.14 279 942721 20734 109625565
Diffuse large B-cell lymphoma recurrent 23.73 10.14 12 942988 6287 109640012
Aplasia pure red cell 23.70 10.14 28 942972 9550 109636749
Muscle spasms 23.69 10.14 2045 940955 276112 109370187
Skin lesion 23.69 10.14 304 942696 51327 109594972
Disturbance in social behaviour 23.40 10.14 7 942993 5051 109641248
Wrong technique in device usage process 23.34 10.14 15 942985 6886 109639413
Infusion site bruising 23.33 10.14 77 942923 3617 109642682
Hypercholesterolaemia 23.28 10.14 972 942028 89865 109556434
Dysstasia 23.24 10.14 175 942825 32811 109613488
Hyperglycaemia 23.21 10.14 550 942450 84540 109561759
Rebound effect 23.14 10.14 58 942942 14748 109631551
Unresponsive to stimuli 23.12 10.14 710 942290 63080 109583219
Klebsiella infection 23.06 10.14 90 942910 19919 109626380
Glucose tolerance impaired 23.04 10.14 30 942970 9807 109636492
Eye pruritus 23.03 10.14 174 942826 32601 109613698
Drug screen positive 23.01 10.14 112 942888 6298 109640001
Peripheral swelling 22.99 10.14 3850 939150 400184 109246115
Limb discomfort 22.88 10.14 230 942770 40624 109605675
Irritability 22.87 10.14 279 942721 47530 109598769
Eye irritation 22.84 10.14 179 942821 33273 109613026
Arteriosclerosis 22.80 10.14 121 942879 24646 109621653
Intracranial pressure increased 22.77 10.14 161 942839 10374 109635925
Sputum culture positive 22.74 10.14 79 942921 3810 109642489
Galactorrhoea 22.71 10.14 4 942996 4151 109642148
Blood creatine phosphokinase increased 22.62 10.14 463 942537 72614 109573685
Aortic valve stenosis 22.60 10.14 13 942987 6337 109639962
Abdominal pain 22.57 10.14 4825 938175 508164 109138135
Mycobacterial infection 22.57 10.14 5 942995 4412 109641887
Gastric disorder 22.54 10.14 179 942821 33178 109613121
Nocturia 22.54 10.14 72 942928 16918 109629381
Device defective 22.44 10.14 3 942997 3819 109642480
Macular oedema 22.41 10.14 16 942984 6950 109639349
Acute graft versus host disease in intestine 22.38 10.14 10 942990 5629 109640670
Brain stem glioma 22.35 10.14 17 942983 203 109646096
Ventricular extrasystoles 22.33 10.14 108 942892 22533 109623766
Lower limb fracture 22.30 10.14 819 942181 74529 109571770
Injection site nodule 22.29 10.14 6 942994 4640 109641659
Hepatic cancer 22.26 10.14 38 942962 11118 109635181
Embolic stroke 22.24 10.14 25 942975 8718 109637581
Immune effector cell-associated neurotoxicity syndrome 22.23 10.14 208 942792 14574 109631725
Acute myeloid leukaemia recurrent 22.22 10.14 8 942992 5131 109641168
Oral pain 22.16 10.14 208 942792 37236 109609063
Cellulitis 22.15 10.14 864 942136 125152 109521147
Infection reactivation 22.15 10.14 4 942996 4077 109642222
Cryopyrin associated periodic syndrome 22.14 10.14 27 942973 598 109645701
Nail disorder 22.12 10.14 649 942351 57286 109589013
Psoriatic arthropathy 22.08 10.14 1957 941043 194804 109451495
Ovarian hyperstimulation syndrome 22.08 10.14 9 942991 5351 109640948
Leukaemia 22.00 10.14 19 942981 7499 109638800
Iron deficiency anaemia 21.96 10.14 168 942832 31391 109614908
Carotid artery thrombosis 21.84 10.14 149 942851 9489 109636810
Total lung capacity increased 21.83 10.14 94 942906 5018 109641281
Head injury 21.75 10.14 248 942752 42769 109603530
White coat hypertension 21.74 10.14 40 942960 1291 109645008
Postmortem blood drug level increased 21.70 10.14 38 942962 1179 109645120
Cardiovascular disorder 21.63 10.14 110 942890 22650 109623649
Epstein-Barr virus associated lymphoproliferative disorder 21.58 10.14 7 942993 4795 109641504
Fear 21.53 10.14 113 942887 23080 109623219
Condition aggravated 21.48 10.14 5756 937244 729080 108917219
Application site pain 21.44 10.14 10 942990 5489 109640810
Lipodystrophy acquired 21.41 10.14 6 942994 4518 109641781
Hepatitis 21.38 10.14 956 942044 89098 109557201
Device deployment issue 21.36 10.14 5 942995 4248 109642051
Electrolyte imbalance 21.35 10.14 207 942793 36821 109609478
Spinal operation 21.32 10.14 38 942962 10934 109635365
Gestational diabetes 21.23 10.14 19 942981 7370 109638929
Acute generalised exanthematous pustulosis 21.19 10.14 280 942720 21384 109624915
Skin irritation 21.06 10.14 70 942930 16249 109630050
Urine bilirubin decreased 21.04 10.14 14 942986 133 109646166
Liver function test increased 21.02 10.14 940 942060 87608 109558691
Hypersensitivity vasculitis 20.96 10.14 17 942983 6920 109639379
Anger 20.95 10.14 87 942913 18920 109627379
Ejection fraction decreased 20.93 10.14 235 942765 40645 109605654
Vital capacity decreased 20.72 10.14 51 942949 2022 109644277
Aspartate aminotransferase increased 20.70 10.14 1608 941392 158328 109487971
Panniculitis 20.69 10.14 66 942934 15516 109630783
Muscle disorder 20.60 10.14 16 942984 6656 109639643
Personality change 20.58 10.14 39 942961 10963 109635336
Total lung capacity decreased 20.52 10.14 117 942883 6997 109639302
Therapy non-responder 20.49 10.14 1114 941886 156193 109490106
Skin cancer 20.49 10.14 80 942920 17704 109628595
Mite allergy 20.48 10.14 12 942988 5791 109640508
Gastrointestinal toxicity 20.44 10.14 40 942960 11108 109635191
Metastases to lymph nodes 20.43 10.14 63 942937 14969 109631330
Exposure to SARS-CoV-2 20.40 10.14 63 942937 2856 109643443
Uterine perforation 20.37 10.14 17 942983 6823 109639476
Pollakiuria 20.36 10.14 260 942740 43935 109602364
Anti-cyclic citrullinated peptide antibody 20.35 10.14 260 942740 19704 109626595
Ischaemic cardiomyopathy 20.27 10.14 23 942977 7988 109638311
Coordination abnormal 20.26 10.14 315 942685 24913 109621386
Granuloma skin 20.24 10.14 41 942959 11242 109635057
Coagulation factor V level decreased 20.24 10.14 27 942973 656 109645643
Eyelid ptosis 20.22 10.14 53 942947 13274 109633025
Generalised tonic-clonic seizure 20.18 10.14 336 942664 54344 109591955
Metastases to central nervous system 20.17 10.14 113 942887 22704 109623595
Device failure 20.15 10.14 19 942981 7188 109639111
Large intestine polyp 20.09 10.14 64 942936 15053 109631246
Lactic acidosis 20.08 10.14 620 942380 92191 109554108
Mania 20.05 10.14 100 942900 20696 109625603
Gingival hypertrophy 20.03 10.14 6 942994 4325 109641974
Abdominal pain upper 20.00 10.14 3328 939672 345783 109300516
Ventricular hypokinesia 19.90 10.14 41 942959 11173 109635126
B-cell lymphoma 19.84 10.14 19 942981 7135 109639164
Rheumatoid lung 19.84 10.14 6 942994 4298 109642001
Spinal compression fracture 19.77 10.14 85 942915 18307 109627992
Bacterial test 19.76 10.14 36 942964 1153 109645146
Embedded device 19.75 10.14 5 942995 4028 109642271
Hepatitis cholestatic 19.74 10.14 233 942767 17333 109628966
Akathisia 19.70 10.14 77 942923 17036 109629263
SJS-TEN overlap 19.69 10.14 47 942953 1827 109644472
Ischaemic stroke 19.66 10.14 241 942759 41022 109605277
Lung infiltration 19.64 10.14 126 942874 24502 109621797
Glutathione decreased 19.63 10.14 10 942990 54 109646245
Nasal necrosis 19.59 10.14 15 942985 181 109646118
Leukoencephalopathy 19.59 10.14 30 942970 9165 109637134
Postoperative delirium 19.57 10.14 31 942969 884 109645415
Injection site discomfort 19.56 10.14 18 942982 6889 109639410
Pericardial haemorrhage 19.56 10.14 10 942990 5207 109641092
Myocardial ischaemia 19.55 10.14 140 942860 26544 109619755
Ketoacidosis 19.54 10.14 35 942965 10052 109636247
Polydipsia 19.54 10.14 22 942978 7666 109638633
Spinal osteoarthritis 19.49 10.14 97 942903 20086 109626213
Infection 19.46 10.14 3441 939559 358759 109287540
Transplant failure 19.40 10.14 12 942988 5623 109640676
Drug eruption 19.39 10.14 331 942669 53328 109592971
Symmetrical drug-related intertriginous and flexural exanthema 19.31 10.14 47 942953 1850 109644449
Neoplasm malignant 19.22 10.14 213 942787 36930 109609369
Stevens-Johnson syndrome 19.18 10.14 530 942470 46371 109599928
Viral haemorrhagic cystitis 19.18 10.14 3 942997 3396 109642903
Parvimonas micra infection 19.17 10.14 11 942989 78 109646221
Lymphocyte count decreased 19.14 10.14 631 942369 56612 109589687
Peritonitis bacterial 19.13 10.14 38 942962 10495 109635804
Viral load increased 19.11 10.14 3 942997 3387 109642912
Dust allergy 19.03 10.14 14 942986 5987 109640312
Metabolic disorder 19.02 10.14 38 942962 10472 109635827
Pyrexia 19.00 10.14 8203 934797 890062 108756237
Cardiac operation 18.99 10.14 14 942986 5981 109640318
Blepharospasm 18.95 10.14 607 942393 54244 109592055
Rhinalgia 18.94 10.14 75 942925 3854 109642445
Hepatitis B 18.94 10.14 33 942967 9579 109636720
Hypophagia 18.90 10.14 325 942675 52301 109593998
Skin discolouration 18.89 10.14 299 942701 48747 109597552
Hyperthyroidism 18.87 10.14 159 942841 29102 109617197
Amenorrhoea 18.83 10.14 31 942969 9200 109637099
Mood altered 18.81 10.14 106 942894 21269 109625030
Local anaesthetic systemic toxicity 18.78 10.14 12 942988 5525 109640774
Rhabdomyolysis 18.73 10.14 837 942163 119564 109526735
Injury associated with device 18.69 10.14 7 942993 4382 109641917
Premature delivery 18.62 10.14 169 942831 30463 109615836
Paresis 18.59 10.14 9 942991 4835 109641464
Temperature regulation disorder 18.56 10.14 179 942821 12647 109633652
Product dispensing error 18.53 10.14 74 942926 16271 109630028
Device breakage 18.51 10.14 58 942942 13711 109632588
Epstein-Barr viraemia 18.39 10.14 4 942996 3575 109642724
Allergy test negative 18.38 10.14 20 942980 390 109645909
Lung neoplasm malignant 18.35 10.14 192 942808 33650 109612649
Mental disorder 18.32 10.14 227 942773 38564 109607735
Pemphigoid 18.30 10.14 96 942904 19611 109626688
Polycystic ovaries 18.27 10.14 9 942991 4787 109641512
Normochromic normocytic anaemia 18.27 10.14 54 942946 13003 109633296
Neoplasm recurrence 18.21 10.14 11 942989 5221 109641078
Fungal infection 18.17 10.14 314 942686 50492 109595807
Peripheral arterial occlusive disease 18.16 10.14 32 942968 9248 109637051
Mononeuropathy 18.14 10.14 19 942981 354 109645945
Coronary artery occlusion 18.14 10.14 71 942929 15701 109630598
Liver disorder 18.06 10.14 1428 941572 140815 109505484
Coronary artery bypass 18.01 10.14 15 942985 6027 109640272
Cyanosis neonatal 18.01 10.14 10 942990 66 109646233
Tuberculosis 17.99 10.14 84 942916 17690 109628609
Adulterated product 17.98 10.14 34 942966 1121 109645178
Fanconi syndrome 17.95 10.14 4 942996 3515 109642784
Dysphoria 17.91 10.14 17 942983 6411 109639888
Cystic fibrosis 17.84 10.14 9 942991 4722 109641577
Multiple organ dysfunction syndrome 17.83 10.14 1085 941915 150625 109495674
Metabolic alkalosis 17.81 10.14 13 942987 5582 109640717
Skin disorder 17.77 10.14 258 942742 42655 109603644
Hypokinesia 17.75 10.14 111 942889 21715 109624584
Eye haemorrhage 17.73 10.14 47 942953 11727 109634572
Anuria 17.69 10.14 128 942872 24213 109622086
Impaired quality of life 17.65 10.14 167 942833 29850 109616449
Dysuria 17.65 10.14 385 942615 59846 109586453
Injection site irritation 17.64 10.14 10 942990 4914 109641385
Hypopnoea 17.56 10.14 161 942839 11219 109635080
Hepatitis E 17.55 10.14 8 942992 4451 109641848
Neurological symptom 17.48 10.14 71 942929 15537 109630762
Pulmonary tuberculosis 17.45 10.14 32 942968 9107 109637192
Granuloma 17.44 10.14 34 942966 9456 109636843
Gynaecomastia 17.44 10.14 34 942966 9456 109636843
International normalised ratio increased 17.40 10.14 906 942094 85866 109560433
High density lipoprotein decreased 17.38 10.14 14 942986 5719 109640580
Haemolysis 17.38 10.14 207 942793 15432 109630867
Paradoxical drug reaction 17.33 10.14 36 942964 9781 109636518
Anaphylactic reaction 17.33 10.14 1164 941836 113136 109533163
Hypertransaminasaemia 17.30 10.14 297 942703 23958 109622341
Erysipelas 17.29 10.14 56 942944 13102 109633197
Device related infection 17.28 10.14 235 942765 39284 109607015
Administration site swelling 17.27 10.14 24 942976 607 109645692
Road traffic accident 17.23 10.14 1099 941901 106299 109540000
Cryptococcosis 17.18 10.14 9 942991 4622 109641677
Femur fracture 17.16 10.14 271 942729 44198 109602101
Adrenal insufficiency 17.15 10.14 256 942744 42134 109604165
Lupus vulgaris 17.14 10.14 394 942606 33489 109612810
Tooth injury 17.13 10.14 50 942950 2196 109644103
Ductus arteriosus premature closure 17.11 10.14 11 942989 98 109646201
Akinesia 17.10 10.14 5 942995 3662 109642637
Dyspnoea at rest 17.05 10.14 28 942972 8318 109637981
Underdose 17.00 10.14 412 942588 63142 109583157
Histoplasmosis disseminated 16.97 10.14 6 942994 3893 109642406
Secretion discharge 16.96 10.14 102 942898 20142 109626157
Cutaneous T-cell lymphoma 16.95 10.14 4 942996 3380 109642919
Blood glucose abnormal 16.95 10.14 55 942945 12861 109633438
Fluid retention 16.92 10.14 645 942355 93662 109552637
Intentional dose omission 16.91 10.14 101 942899 19979 109626320
Dry eye 16.82 10.14 355 942645 55438 109590861
Sleep apnoea syndrome 16.81 10.14 243 942757 40204 109606095
Extrapyramidal disorder 16.80 10.14 161 942839 28706 109617593
Adjustment disorder 16.79 10.14 153 942847 10642 109635657
Respiratory disorder 16.77 10.14 757 942243 70625 109575674
Heavy menstrual bleeding 16.76 10.14 77 942923 16288 109630011
Arterial occlusive disease 16.74 10.14 202 942798 15106 109631193
Leukocytosis 16.64 10.14 588 942412 53240 109593059
Focal dyscognitive seizures 16.63 10.14 6 942994 3843 109642456
Partial seizures 16.56 10.14 46 942954 11303 109634996
Supraventricular tachycardia 16.53 10.14 131 942869 24291 109622008
Hyperprolactinaemia 16.51 10.14 19 942981 6556 109639743
Adenovirus infection 16.47 10.14 44 942956 10950 109635349
Prothrombin time prolonged 16.43 10.14 222 942778 17039 109629260
Squamous cell carcinoma of skin 16.43 10.14 83 942917 17120 109629179
Foot operation 16.42 10.14 23 942977 7290 109639009
Potentiating drug interaction 16.40 10.14 48 942952 11595 109634704
Progressive multifocal leukoencephalopathy 16.37 10.14 135 942865 24821 109621478
Haemoptysis 16.35 10.14 473 942527 70881 109575418
Liver transplant 16.34 10.14 80 942920 4509 109641790
Disseminated tuberculosis 16.32 10.14 12 942988 5134 109641165
Glomerular filtration rate decreased 16.22 10.14 163 942837 28793 109617506
Polyarthritis 16.17 10.14 95 942905 18868 109627431
Hypoglycaemic coma 16.17 10.14 14 942986 5519 109640780
Osteolysis 16.11 10.14 14 942986 5509 109640790
Weight decreased 16.08 10.14 3639 939361 464418 109181881
Restrictive pulmonary disease 16.04 10.14 4 942996 3255 109643044
Alcoholic coma 15.94 10.14 10 942990 85 109646214
Prostatic pain 15.94 10.14 16 942984 283 109646016
Clonus 15.91 10.14 128 942872 8588 109637711
Pre-eclampsia 15.89 10.14 31 942969 8619 109637680
Nephrogenic systemic fibrosis 15.87 10.14 14 942986 5469 109640830
Mycobacterium avium complex infection 15.85 10.14 16 942984 5861 109640438
Thirst 15.85 10.14 114 942886 21593 109624706
Coagulation factor decreased 15.85 10.14 17 942983 326 109645973
Pharyngeal oedema 15.83 10.14 79 942921 16349 109629950
Withdrawal syndrome 15.83 10.14 181 942819 31199 109615100
Diabetic neuropathy 15.73 10.14 22 942978 6977 109639322
Petit mal epilepsy 15.72 10.14 25 942975 7522 109638777
Intestinal obstruction 15.66 10.14 340 942660 52887 109593412
Fungal rhinitis 15.66 10.14 10 942990 88 109646211
Hallucination 15.60 10.14 706 942294 100726 109545573
Concomitant disease aggravated 15.60 10.14 79 942921 16285 109630014
Asthma 15.57 10.14 1882 941118 248409 109397890
Groin pain 15.56 10.14 73 942927 15355 109630944
Neonatal respiratory acidosis 15.55 10.14 9 942991 65 109646234
Dysgeusia 15.52 10.14 466 942534 69519 109576780
Blood creatinine decreased 15.51 10.14 132 942868 9005 109637294
Gangrene 15.48 10.14 210 942790 16131 109630168
Catheter site bruise 15.46 10.14 22 942978 569 109645730
Focal segmental glomerulosclerosis 15.46 10.14 8 942992 4137 109642162
Red blood cells urine positive 15.43 10.14 86 942914 5099 109641200
Catheterisation cardiac 15.42 10.14 18 942982 6173 109640126
Harlequin syndrome 15.37 10.14 15 942985 256 109646043
Complication associated with device 15.35 10.14 104 942896 19969 109626330
Burning sensation 15.31 10.14 461 942539 68751 109577548
Nutritional supplementation 15.30 10.14 8 942992 46 109646253
Monoparesis 15.26 10.14 10 942990 4543 109641756
Flushing 15.24 10.14 1063 941937 103673 109542626
Blood immunoglobulin A decreased 15.23 10.14 48 942952 2200 109644099
Anti-erythrocyte antibody positive 15.22 10.14 9 942991 68 109646231
Coagulation factor X level decreased 15.20 10.14 10 942990 93 109646206
Drug provocation test 15.20 10.14 7 942993 29 109646270
Encephalopathy 15.19 10.14 841 942159 80214 109566085
Administration site bruise 15.17 10.14 14 942986 222 109646077
Unmasking of previously unidentified disease 15.16 10.14 3 942997 2865 109643434
Bone disorder 15.13 10.14 112 942888 21080 109625219
Infusion site discomfort 15.09 10.14 42 942958 1795 109644504
Stent placement 15.03 10.14 24 942976 7210 109639089
Amniotic cavity disorder 15.03 10.14 8 942992 48 109646251
Movement disorder 15.03 10.14 219 942781 36185 109610114
Brain scan abnormal 15.02 10.14 38 942962 1533 109644766
Dystonia 14.99 10.14 144 942856 25661 109620638
Plasma cell myeloma recurrent 14.98 10.14 23 942977 7019 109639280
Herpes zoster 14.96 10.14 763 942237 107616 109538683
Cells in urine 14.94 10.14 13 942987 190 109646109
Tetany 14.93 10.14 6 942994 3598 109642701
Systemic mycosis 14.87 10.14 7 942993 3822 109642477
Skin fissures 14.84 10.14 135 942865 24323 109621976
Hiatus hernia 14.81 10.14 157 942843 27449 109618850
Loss of employment 14.81 10.14 5 942995 3339 109642960
Lymphoma 14.69 10.14 106 942894 20065 109626234
Urine analysis abnormal 14.67 10.14 105 942895 6792 109639507
Cachexia 14.66 10.14 59 942941 12946 109633353
Abnormal loss of weight 14.66 10.14 42 942958 10215 109636084
Nodule 14.65 10.14 193 942807 32438 109613861
Fear of injection 14.64 10.14 34 942966 8877 109637422
Migraine 14.59 10.14 1675 941325 169977 109476322
Cardiac murmur 14.59 10.14 293 942707 24335 109621964
Cerebral artery thrombosis 14.56 10.14 39 942961 1629 109644670
Coronary artery stenosis 14.53 10.14 64 942936 13694 109632605
Atypical femur fracture 14.53 10.14 19 942981 6200 109640099
Thyroid neoplasm 14.51 10.14 5 942995 3296 109643003
Blood loss anaemia 14.49 10.14 92 942908 17933 109628366
Back injury 14.47 10.14 517 942483 46882 109599417
Incorrect dosage administered 14.45 10.14 69 942931 3849 109642450
Goitre 14.45 10.14 19 942981 6185 109640114
Bronchopulmonary aspergillosis allergic 14.44 10.14 122 942878 8304 109637995
Post cholecystectomy syndrome 14.42 10.14 26 942974 826 109645473
Anhedonia 14.41 10.14 75 942925 15353 109630946
Product physical issue 14.41 10.14 13 942987 5023 109641276
Nail bed inflammation 14.36 10.14 44 942956 1986 109644313
Granulocyte count decreased 14.34 10.14 8 942992 3966 109642333
Application site erythema 14.31 10.14 16 942984 5594 109640705
Ataxia 14.29 10.14 176 942824 29932 109616367
Skin weeping 14.24 10.14 7 942993 3728 109642571
Pain of skin 14.23 10.14 106 942894 19923 109626376
Colon cancer 14.23 10.14 82 942918 16361 109629938
Uterine cancer 14.22 10.14 9 942991 4165 109642134
Transfusion-related circulatory overload 14.20 10.14 27 942973 894 109645405
Dyslipidaemia 14.15 10.14 79 942921 15886 109630413
Rheumatoid nodule 14.14 10.14 108 942892 20188 109626111
Nasal septum perforation 14.13 10.14 27 942973 897 109645402
Sphincter of Oddi dysfunction 14.09 10.14 21 942979 567 109645732
Toxoplasmosis 14.07 10.14 5 942995 3234 109643065
Sensitisation 14.07 10.14 9 942991 4142 109642157
Consciousness fluctuating 14.07 10.14 46 942954 2150 109644149
Pelvic pain 14.06 10.14 79 942921 15863 109630436
Haematemesis 14.00 10.14 390 942610 58718 109587581
Neonatal respiratory distress syndrome 13.99 10.14 17 942983 375 109645924
Reversible airways obstruction 13.95 10.14 50 942950 2449 109643850
Lymphocyte count abnormal 13.94 10.14 49 942951 2377 109643922
Renal failure neonatal 13.93 10.14 9 942991 81 109646218
Pregnancy with contraceptive device 13.90 10.14 8 942992 3899 109642400
Peritonitis 13.87 10.14 195 942805 32412 109613887
Oesophageal candidiasis 13.86 10.14 51 942949 11483 109634816
Invasive ductal breast carcinoma 13.86 10.14 22 942978 6624 109639675
Musculoskeletal disorder 13.80 10.14 125 942875 22539 109623760
Transferrin decreased 13.75 10.14 20 942980 528 109645771
Asthma-chronic obstructive pulmonary disease overlap syndrome 13.74 10.14 97 942903 6247 109640052
Splenomegaly 13.69 10.14 138 942862 24360 109621939
Malignant melanoma 13.68 10.14 86 942914 16805 109629494
Pupillary light reflex tests abnormal 13.68 10.14 17 942983 384 109645915
Abortion induced 13.66 10.14 30 942970 7989 109638310
Bradycardia neonatal 13.66 10.14 9 942991 84 109646215
Specific gravity urine abnormal 13.66 10.14 9 942991 84 109646215
Caesarean section 13.57 10.14 66 942934 13751 109632548
Acute fatty liver of pregnancy 13.57 10.14 7 942993 39 109646260
Therapy change 13.52 10.14 42 942958 9955 109636344
Intermenstrual bleeding 13.49 10.14 24 942976 6910 109639389
Right ventricle outflow tract obstruction 13.47 10.14 8 942992 61 109646238
Secondary immunodeficiency 13.46 10.14 12 942988 4664 109641635
Hypoacusis 13.40 10.14 215 942785 34976 109611323
Diffuse large B-cell lymphoma 13.37 10.14 80 942920 15818 109630481
Bone lesion 13.37 10.14 25 942975 7062 109639237
Enterobacter infection 13.32 10.14 18 942982 5793 109640506
Neuroblastoma 13.27 10.14 16 942984 350 109645949
Granulomatosis with polyangiitis 13.27 10.14 62 942938 3428 109642871
Smear cervix abnormal 13.26 10.14 52 942948 2660 109643639
Foetal heart rate abnormal 13.25 10.14 22 942978 653 109645646
Gastrointestinal pain 13.25 10.14 54 942946 11806 109634493
Metastasis 13.22 10.14 32 942968 8235 109638064
Drug effective for unapproved indication 13.16 10.14 69 942931 14098 109632201
Gingival bleeding 13.16 10.14 107 942893 19732 109626567
Inflammatory marker increased 13.15 10.14 71 942929 14398 109631901
Photosensitivity reaction 13.14 10.14 147 942853 25442 109620857
Deafness 13.11 10.14 155 942845 26554 109619745
Vein rupture 13.10 10.14 50 942950 2525 109643774
Foreign body sensation in eyes 13.10 10.14 6 942994 3328 109642971
Psychiatric decompensation 13.08 10.14 18 942982 5747 109640552
Stress cardiomyopathy 13.05 10.14 80 942920 15726 109630573
Emotional distress 13.04 10.14 287 942713 44560 109601739
Ophthalmoplegia 13.02 10.14 7 942993 3543 109642756
Throat tightness 13.02 10.14 376 942624 33113 109613186
Diarrhoea haemorrhagic 13.00 10.14 79 942921 15560 109630739
Bradycardia 12.99 10.14 1145 941855 154372 109491927
Mood swings 12.95 10.14 128 942872 22684 109623615
Hip arthroplasty 12.92 10.14 591 942409 55222 109591077
Frostbite 12.91 10.14 14 942986 272 109646027
Flatulence 12.90 10.14 342 942658 51807 109594492
Gastroenteritis 12.86 10.14 243 942757 38557 109607742
Infusion site haemorrhage 12.86 10.14 75 942925 4523 109641776
Enteritis 12.85 10.14 103 942897 19053 109627246
Chest pain 12.85 10.14 2927 940073 373448 109272851
Substance abuser 12.84 10.14 18 942982 459 109645840
Application site pruritus 12.81 10.14 10 942990 4150 109642149
Catheter management 12.80 10.14 8 942992 3727 109642572
Drooling 12.76 10.14 26 942974 7113 109639186
Disorientation 12.75 10.14 483 942517 70188 109576111
Urinary incontinence 12.72 10.14 316 942684 48271 109598028
Central nervous system lesion 12.70 10.14 79 942921 15474 109630825
Porphyria acute 12.70 10.14 228 942772 18552 109627747
Sinus congestion 12.68 10.14 345 942655 30114 109616185
Drug tolerance 12.65 10.14 86 942914 16499 109629800
Thrombotic thrombocytopenic purpura 12.62 10.14 26 942974 7085 109639214
Culture urine positive 12.62 10.14 77 942923 4719 109641580
Febrile bone marrow aplasia 12.61 10.14 92 942908 17373 109628926
Head discomfort 12.61 10.14 230 942770 18770 109627529
Gastritis erosive 12.57 10.14 56 942944 11944 109634355
Immunosuppressant drug level decreased 12.52 10.14 4 942996 2767 109643532
Intentional product misuse to child 12.52 10.14 12 942988 200 109646099
Alpha 1 microglobulin increased 12.51 10.14 7 942993 47 109646252
Urinary casts 12.50 10.14 32 942968 1300 109644999
Arteriospasm coronary 12.47 10.14 38 942962 9062 109637237
Encephalitis viral 12.47 10.14 5 942995 3002 109643297
Palpitations 12.46 10.14 1178 941822 158034 109488265
Product adhesion issue 12.46 10.14 5 942995 3001 109643298
Osteopenia 12.45 10.14 125 942875 22084 109624215
Pleurothotonus 12.42 10.14 3 942997 2495 109643804
Juvenile idiopathic arthritis 12.41 10.14 20 942980 5987 109640312
Obsessive-compulsive disorder 12.41 10.14 27 942973 7214 109639085
Haemorrhage intracranial 12.40 10.14 173 942827 28796 109617503
Herpes simplex 12.39 10.14 81 942919 15683 109630616
Blood phosphorus increased 12.36 10.14 202 942798 16138 109630161
Blood test abnormal 12.34 10.14 325 942675 28229 109618070
Supraventricular extrasystoles 12.33 10.14 32 942968 8041 109638258
Interleukin level increased 12.28 10.14 36 942964 1585 109644714
Soft tissue disorder 12.24 10.14 61 942939 3463 109642836
Tooth extraction 12.22 10.14 63 942937 12928 109633371
Abdominal pain lower 12.21 10.14 234 942766 37049 109609250
Beta haemolytic streptococcal infection 12.20 10.14 54 942946 2917 109643382
Knee operation 12.19 10.14 26 942974 6996 109639303
Renal mass 12.16 10.14 8 942992 3627 109642672
Alcohol poisoning 12.14 10.14 124 942876 8896 109637403
Death 12.11 10.14 6342 936658 692527 108953772
Skin mass 12.06 10.14 43 942957 9773 109636526
Systemic candida 12.05 10.14 44 942956 9930 109636369
Facial paresis 12.03 10.14 21 942979 6092 109640207
Left ventricular failure 12.02 10.14 53 942947 11336 109634963
Pleuritic pain 12.01 10.14 199 942801 15941 109630358
Hip fracture 12.01 10.14 219 942781 34932 109611367
Lacunar infarction 12.01 10.14 22 942978 6264 109640035
Tongue biting 12.00 10.14 5 942995 2934 109643365
Bone marrow disorder 11.97 10.14 11 942989 4212 109642087
Unintended pregnancy 11.96 10.14 14 942986 4794 109641505
Monocyte percentage increased 11.95 10.14 45 942955 2258 109644041
Allodynia 11.91 10.14 42 942958 2041 109644258
Walking aid user 11.90 10.14 289 942711 24786 109621513
Eosinophil percentage increased 11.86 10.14 35 942965 1547 109644752
Pneumocystis jirovecii infection 11.84 10.14 12 942988 4388 109641911
Vanishing bile duct syndrome 11.84 10.14 56 942944 3112 109643187
Long QT syndrome 11.83 10.14 27 942973 7091 109639208
Severe invasive streptococcal infection 11.82 10.14 7 942993 53 109646246
Fatigue 11.82 10.14 9880 933120 1206078 108440221
Apparent death 11.75 10.14 5 942995 2897 109643402
Injection site haematoma 11.74 10.14 16 942984 5130 109641169
Prescribed overdose 11.74 10.14 883 942117 86698 109559601
Dependent personality disorder 11.73 10.14 9 942991 109 109646190
Nasal obstruction 11.72 10.14 7 942993 3343 109642956
Cardiac dysfunction 11.69 10.14 22 942978 6201 109640098
Atrioventricular block 11.67 10.14 90 942910 16787 109629512
Orbital compartment syndrome 11.66 10.14 9 942991 110 109646189
Thyroid cancer 11.65 10.14 22 942978 6192 109640107
Pulmonary toxicity 11.64 10.14 96 942904 17650 109628649
Panic attack 11.63 10.14 175 942825 28765 109617534
Pancreatic carcinoma metastatic 11.62 10.14 11 942989 4153 109642146
Haemoglobin urine present 11.60 10.14 25 942975 907 109645392
Post-traumatic stress disorder 11.57 10.14 96 942904 6500 109639799
Lung opacity 11.56 10.14 151 942849 11501 109634798
Anti factor V antibody 11.55 10.14 14 942986 308 109645991
Sinus node dysfunction 11.54 10.14 39 942961 9008 109637291
Immune-mediated myositis 11.51 10.14 22 942978 6164 109640135
Teething 11.50 10.14 10 942990 146 109646153
Lung transplant 11.50 10.14 17 942983 5269 109641030
Hyperaesthesia 11.49 10.14 183 942817 14544 109631755
Product residue present 11.48 10.14 10 942990 3931 109642368
Left ventricular hypertrophy 11.48 10.14 66 942934 13178 109633121
Adverse reaction 11.43 10.14 332 942668 29262 109617037
Angina pectoris 11.41 10.14 425 942575 61870 109584429
Base excess 11.41 10.14 7 942993 57 109646242
Alanine aminotransferase abnormal 11.40 10.14 41 942959 9293 109637006
Musculoskeletal discomfort 11.39 10.14 137 942863 23401 109622898
Renal cell carcinoma 11.38 10.14 30 942970 7500 109638799
Bacterial test positive 11.38 10.14 111 942889 7866 109638433
Creatinine renal clearance increased 11.38 10.14 61 942939 3564 109642735
Aphasia 11.37 10.14 400 942600 58597 109587702
Blood immunoglobulin G decreased 11.37 10.14 82 942918 5318 109640981
Diabetic nephropathy 11.36 10.14 8 942992 3500 109642799
Gait inability 11.35 10.14 1329 941671 135047 109511252
Aminoaciduria 11.35 10.14 15 942985 361 109645938
Balint's syndrome 11.32 10.14 3 942997 0 109646299
Gastritis 11.31 10.14 360 942640 53339 109592960
Blindness unilateral 11.29 10.14 44 942956 9742 109636557
Haemorrhagic diathesis 11.28 10.14 30 942970 7478 109638821
Tumour marker increased 11.28 10.14 16 942984 5044 109641255
Sinobronchitis 11.25 10.14 17 942983 465 109645834
Myelofibrosis 11.22 10.14 6 942994 3045 109643254
Bradypnoea 11.21 10.14 118 942882 8531 109637768
Orthopnoea 11.20 10.14 52 942948 10969 109635330
Cholestatic liver injury 11.20 10.14 104 942896 7272 109639027
Diastolic dysfunction 11.20 10.14 61 942939 12343 109633956
Growth retardation 11.20 10.14 4 942996 2578 109643721
Nasal oedema 11.19 10.14 98 942902 6741 109639558
Mechanical ventilation complication 11.15 10.14 22 942978 749 109645550
Injection site vesicles 11.14 10.14 13 942987 4458 109641841
Libido decreased 11.14 10.14 21 942979 5914 109640385
Product administered at inappropriate site 11.10 10.14 18 942982 5375 109640924
Fanconi syndrome acquired 11.10 10.14 6 942994 3028 109643271
Nephropathy toxic 11.10 10.14 166 942834 27312 109618987
Clostridium difficile infection 11.09 10.14 349 942651 51780 109594519
Embolism venous 11.08 10.14 16 942984 5007 109641292
Band neutrophil count increased 11.07 10.14 21 942979 694 109645605
Electrocardiogram abnormal 11.04 10.14 104 942896 18605 109627694
Brain abscess 11.01 10.14 26 942974 6748 109639551
Ear infection 11.01 10.14 647 942353 62085 109584214
Premature rupture of membranes 11.01 10.14 14 942986 4623 109641676
Respiratory alkalosis 10.98 10.14 85 942915 5636 109640663
Haemophagocytic lymphohistiocytosis 10.98 10.14 196 942804 31363 109614936
Mean cell haemoglobin concentration increased 10.94 10.14 27 942973 1072 109645227
Hyperglycaemic hyperosmolar nonketotic syndrome 10.94 10.14 6 942994 3003 109643296
Red blood cell count decreased 10.93 10.14 455 942545 65468 109580831
Diverticulum intestinal 10.93 10.14 57 942943 11662 109634637
Sinus tachycardia 10.93 10.14 474 942526 44019 109602280
Laboratory test abnormal 10.92 10.14 289 942711 43790 109602509
Nitrite urine present 10.91 10.14 29 942971 1206 109645093
Hepatic perfusion disorder 10.83 10.14 7 942993 63 109646236
Blood urine present 10.78 10.14 277 942723 23968 109622331
Maple syrup disease 10.77 10.14 4 942996 8 109646291
Dialysis 10.76 10.14 111 942889 19508 109626791
Psychomotor skills impaired 10.76 10.14 28 942972 7030 109639269
Stenotrophomonas infection 10.76 10.14 21 942979 5837 109640462
Epidermal necrosis 10.74 10.14 53 942947 2997 109643302
Food allergy 10.73 10.14 234 942766 19714 109626585
Stoma site dermatitis 10.73 10.14 13 942987 286 109646013
Exposed bone in jaw 10.71 10.14 10 942990 3801 109642498
Retinal vein occlusion 10.70 10.14 11 942989 3996 109642303
Pseudomonas infection 10.66 10.14 170 942830 27683 109618616
Drug level below therapeutic 10.65 10.14 149 942851 11524 109634775
Pre-existing condition improved 10.64 10.14 25 942975 6501 109639798
Infusion site discharge 10.61 10.14 39 942961 1934 109644365
Obesity 10.59 10.14 1113 941887 112238 109534061
Multiple allergies 10.58 10.14 155 942845 12108 109634191
Histoplasmosis 10.58 10.14 6 942994 2947 109643352
Sternal fracture 10.54 10.14 56 942944 3260 109643039
Cardiac tamponade 10.54 10.14 55 942945 11252 109635047
Ischaemic cerebral infarction 10.52 10.14 6 942994 2939 109643360
Burn oesophageal 10.52 10.14 16 942984 440 109645859
Serum sickness 10.52 10.14 69 942931 4337 109641962
Portal hypertension 10.50 10.14 38 942962 8599 109637700
Mental impairment 10.49 10.14 133 942867 22506 109623793
Acinetobacter infection 10.49 10.14 9 942991 3564 109642735
Diffuse large B-cell lymphoma refractory 10.49 10.14 46 942954 2475 109643824
Urine bilirubin increased 10.49 10.14 9 942991 129 109646170
Device occlusion 10.49 10.14 81 942919 15104 109631195
Angiokeratoma 10.46 10.14 11 942989 206 109646093
Lung carcinoma cell type unspecified stage IV 10.42 10.14 3 942997 2219 109644080
Disseminated intravascular coagulation 10.41 10.14 270 942730 41016 109605283
Obstructive defaecation 10.41 10.14 12 942988 250 109646049
Carotid artery occlusion 10.41 10.14 44 942956 9521 109636778
Metastases to peritoneum 10.40 10.14 20 942980 5590 109640709
Uterine leiomyoma 10.38 10.14 33 942967 7767 109638532
Therapeutic response shortened 10.38 10.14 328 942672 29255 109617044
Fibrin D dimer increased 10.37 10.14 129 942871 9716 109636583
Erythema annulare 10.35 10.14 13 942987 297 109646002
Hysterectomy 10.34 10.14 35 942965 8079 109638220
Kussmaul respiration 10.31 10.14 16 942984 448 109645851
Ototoxicity 10.30 10.14 12 942988 4119 109642180
Hip surgery 10.30 10.14 12 942988 4118 109642181
Hepatitis toxic 10.29 10.14 86 942914 5835 109640464
Pneumonia cytomegaloviral 10.29 10.14 28 942972 6926 109639373
Analgesic therapy 10.28 10.14 30 942970 7254 109639045
Escherichia infection 10.28 10.14 142 942858 23674 109622625
Hypotensive crisis 10.28 10.14 10 942990 170 109646129
Lyme disease 10.28 10.14 13 942987 4303 109641996
Cystitis 10.28 10.14 674 942326 65362 109580937
Trichoglossia 10.27 10.14 23 942977 857 109645442
Haematoma 10.26 10.14 401 942599 58075 109588224
Renal transplant failure 10.26 10.14 5 942995 2675 109643624
Necrotic lymphadenopathy 10.25 10.14 11 942989 211 109646088
Nephrogenic diabetes insipidus 10.25 10.14 4 942996 2441 109643858
Hypoxia 10.23 10.14 1258 941742 128257 109518042
Paraesthesia 10.23 10.14 2142 940858 274379 109371920
Prothrombin time abnormal 10.23 10.14 29 942971 1253 109645046
Metabolic myopathy 10.21 10.14 9 942991 134 109646165
Gambling disorder 10.20 10.14 3 942997 2188 109644111
Drug-disease interaction 10.19 10.14 38 942962 1898 109644401
Jaw disorder 10.17 10.14 18 942982 5194 109641105
Chondropathy 10.15 10.14 6 942994 2881 109643418
Viraemia 10.14 10.14 12 942988 4090 109642209

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Accidental overdose 30.46 17.33 15 571 135 113232
Gastrointestinal necrosis 20.52 17.33 9 577 60 113307

Pharmacologic Action:

SourceCodeDescription
ATC N06AX62 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
ATC N07XX59 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
ATC R05DA09 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
Opium alkaloids and derivatives
MeSH PA D000996 Antitussive Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:50910 neurotoxin
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:60643 NMDA receptor antagonist
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:146270 oneirogen
FDA MoA N0000181819 Uncompetitive NMDA Receptor Antagonists
FDA EPC N0000181821 Uncompetitive N-methyl-D-aspartate Receptor Antagonist
FDA MoA N0000182147 Sigma-1 Receptor Agonists
FDA EPC N0000182149 Sigma-1 Agonist

Related Drugs by ATC class:

N06AX Other antidepressants 28 drugs
agomelatinebifemelanebrexanolonebupropiondesvenlafaxineduloxetineesketaminegepironelevomilnacipranmedifoxaminemianserinmilnacipran show all 28 →
N07XX Other nervous system drugs 23 drugs
amifampridinearimoclomoldeutetrabenazineedaravoneeplontersenfampridineinotersen laquinimodlevacetylleucineomaveloxolonepatisiranphenylbutanoic acid show all 23 →
R05DA Opium alkaloids and derivatives 10 drugs
acetyldihydrocodeinecodeinedimemorfanethylmorphinehydrocodonemorphinenormethadonenoscapinepholcodinethebacon

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Rhinitis indication 70076002 DOID:4483
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Headache disorder indication 230461009
Sore throat symptom indication 267102003
Influenza-like symptoms indication 315642008
Major depressive disorder indication 370143000
Fever indication 386661006
Pseudobulbar affect indication 432776007
Mouth Irritation indication
Opioid withdrawal off-label use 87132004
Neurotoxicity caused by methotrexate off-label use 129666005
Metabolic alkalosis contraindication 1388004
Brain damage contraindication 2470005
Anuria contraindication 2472002 DOID:2983
Goiter contraindication 3716002 DOID:12176
Ocular hypertension contraindication 4210003 DOID:9282
Hypocalcemia contraindication 5291005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Hyperkalemia contraindication 14140009
Severe chronic ulcerative colitis contraindication 14311001
Constipation contraindication 14760008 DOID:2089
Hyperbilirubinemia contraindication 14783006 DOID:2741
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Mood swings contraindication 18963009
Pulmonary edema contraindication 19242006 DOID:11396
Lowered convulsive threshold contraindication 19260006
Hashimoto thyroiditis contraindication 21983002
Myocardial infarction contraindication 22298006 DOID:5844
Disorder of the central nervous system contraindication 23853001 DOID:331
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ventricular tachycardia contraindication 25569003
Acute tuberculosis contraindication 25629007
Alcohol intoxication contraindication 25702006
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hypercapnia contraindication 29596007
Torsades de pointes contraindication 31722008
Bronchitis contraindication 32398004 DOID:6132
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Methemoglobinemia contraindication 38959009 DOID:10783
Hypernatremia contraindication 39355002
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acidosis contraindication 51387008
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Left ventricular hypertrophy contraindication 55827005
Peptic reflux disease contraindication 57643001
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Urethral stricture contraindication 76618002
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Decreased respiratory function contraindication 80954004
Disorder of brain contraindication 81308009 DOID:936
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Oliguria contraindication 83128009
Cor pulmonale contraindication 83291003 DOID:8515
Hiatal hernia contraindication 84089009 DOID:12642
Epilepsy contraindication 84757009 DOID:1826
Left heart failure contraindication 85232009
Pulmonary emphysema contraindication 87433001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Dermatitis herpetiformis contraindication 111196000 DOID:8505
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Acute abdominal pain contraindication 116290004
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Deficiency of cytochrome-b>5< reductase contraindication 124184009
Gastrointestinal obstruction contraindication 126765001
Neoplasm of brain contraindication 126952004 DOID:1319
Seizure disorder contraindication 128613002
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Hypomagnesemia contraindication 190855004
Drug-induced psychosis contraindication 191483003 DOID:1742
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Hyporeninemic hypoaldosteronism contraindication 236464008
Bladder outflow obstruction contraindication 236645006
Morbid obesity contraindication 238136002 DOID:11981
Hypocomplementemic urticarial vasculitis contraindication 239945009
Rhabdomyolysis contraindication 240131006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Drowsy contraindication 271782001
Peripheral edema contraindication 271809000
Exacerbation of asthma contraindication 281239006
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Central nervous system depression contraindication 418072004
Dysfunction of sphincter of Oddi contraindication 430887001
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.55 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG;10MG NUEDEXTA OTSUKA AMERICA PHARM N021879 Oct. 29, 2010 RX CAPSULE ORAL 7659282 Aug. 13, 2026 TREATMENT OF PSEUDOBULBAR AFFECT
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 8569328 July 18, 2032 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 8569328 July 18, 2032 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 8569328 July 18, 2032 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10058518 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10064857 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10080727 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10092560 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10092561 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10105361 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10251879 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10463634 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10512643 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10780066 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 10881624 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11007189 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11207281 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING PLASMA LEVELS OF DEXTRORPHAN O-GLUCOURONIDE IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11234946 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11253492 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11273133 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11273134 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11285118 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11285146 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11291638 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11291665 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11298352 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11344544 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11382874 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11419867 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11426370 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11571417 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11590124 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 11617747 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9168234 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9198905 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9205083 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9238032 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9278095 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9314462 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9370513 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9375429 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9408815 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9421176 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9457023 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9457025 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9474731 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9486450 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9700528 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9700553 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9707191 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9763932 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9861595 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9867819 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 9968568 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10058518 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10058518 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10064857 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10064857 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10080727 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10080727 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10092560 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10092560 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10092561 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10092561 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10105327 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10105361 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10105361 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10251879 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10251879 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10463634 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10463634 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10512643 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10512643 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10548857 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10596167 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10596167 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10772850 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10780066 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10780066 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10786469 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10786496 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10786496 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10799497 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10806710 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10806710 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10864209 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10874663 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10874664 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10874665 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10881624 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10881624 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10881657 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10894046 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10894047 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10898453 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10933034 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10945973 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10966941 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10966941 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10966974 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11007189 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11020389 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11058648 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11065248 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11065248 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11090300 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11096937 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11123343 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11123344 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11123344 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11129826 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11141388 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11141416 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11147808 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11185515 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11191739 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11191739 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11197839 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11197839 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11207281 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11207281 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING PLASMA LEVELS OF DEXTRORPHAN O-GLUCOURONIDE IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11213521 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11229640 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11234946 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11234946 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11253491 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11253492 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11253492 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11273133 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11273133 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11273134 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11273134 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11285118 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11285118 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11285146 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11285146 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11291638 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11291638 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11291665 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11291665 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11298351 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11298352 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11298352 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11311534 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11344544 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11344544 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11357744 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11357744 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11364233 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11382874 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11382874 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11419867 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11419867 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11426370 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11426370 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11426401 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11426401 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11433067 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11433067 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11439636 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11439636 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11478468 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11497721 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11510918 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11517542 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11517543 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11524007 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11524008 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11534414 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11534414 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11541021 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11541048 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11571417 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11571417 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11576909 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11576909 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11590124 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11590124 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11596627 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11617728 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11617747 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11617747 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11779579 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11969421 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12109178 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9168234 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9168234 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9198905 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9198905 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9205083 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9205083 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9238032 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9238032 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9278095 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9278095 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9314462 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9314462 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9370513 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9370513 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9375429 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9375429 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9408815 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9408815 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9421176 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9421176 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9457023 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9457023 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9457025 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9457025 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9474731 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9474731 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9486450 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9486450 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9700528 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9700528 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9700553 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9700553 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9707191 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9707191 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY REDUCING A TROUGH EFFECT OF DEXTROMETHORPHAN IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9763932 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9763932 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9861595 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9861595 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9867819 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9867819 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9968568 Nov. 5, 2034 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 9968568 Nov. 5, 2034 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10780064 Jan. 7, 2040 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10925842 Jan. 7, 2040 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10940124 Jan. 7, 2040 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 10966942 Jan. 7, 2040 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 12433884 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO IS AN EXTENSIVE METABOLIZER OF DEXTROMETHORPHAN
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 12472156 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 12576078 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12433884 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO IS AN EXTENSIVE METABOLIZER OF DEXTROMETHORPHAN
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12472156 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12576078 June 5, 2040 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11896563 Dec. 1, 2041 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12390428 Dec. 1, 2041 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL 12472174 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11717518 Jan. 20, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11925636 Jan. 20, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12239642 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12263161 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12310961 Jan. 20, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12357697 Jan. 20, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12472174 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12478622 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12564587 Jan. 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO CONSUMES ALCOHOL, AND WHO REDUCES, BUT DOES NOT DISCONTINUE, CONSUMPTION OF ALCOHOL
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11730706 Jan. 23, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11883373 Jan. 23, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12194005 Jan. 23, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO HAS MODERATE RENAL IMPAIRMENT
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12364674 Jan. 23, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11986444 Feb. 15, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12036191 Feb. 15, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12370154 Feb. 15, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO IS A POOR METABOLIZER OF CYP2D6
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12599576 Feb. 15, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO IS A POOR METABOLIZER OF CYP2D6
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11752144 Feb. 23, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12042473 Feb. 23, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12146889 Feb. 23, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12472155 Feb. 23, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WITH A HISTORY OF DRUG ABUSE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11839612 March 2, 2043 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 11844797 April 20, 2043 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL 12194036 April 20, 2043 THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE IN A PATIENT WHO HAS MODERATE HEPATIC IMPAIRMENT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
105MG;30MG AUVELITY AXSOME N215430 April 30, 2026 RX TABLET, EXTENDED RELEASE ORAL April 30, 2029 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
105MG;45MG AUVELITY AXSOME N215430 Aug. 18, 2022 RX TABLET, EXTENDED RELEASE ORAL April 30, 2029 TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sigma non-opioid intracellular receptor 1 Membrane receptor AGONIST D2 6.46 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 8.84 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter IC50 4.78 CHEMBL
Cytochrome P450 2D6 Enzyme Ks 4.48 WOMBAT-PK
Glutamate receptor ionotropic, NMDA 3A Ion channel ANTAGONIST IC50 5.70 WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C Ion channel BLOCKER IC50 6.33 IUPHAR
Solute carrier family 22 member 1 Transporter IC50 4.98 CHEMBL
Taste receptor type 2 member 46 GPCR EC50 4.51 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.29 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane other IC50 7.82 CHEMBL
Glutamate NMDA receptor Ion channel Ki 5.65 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.89 CHEMBL

External reference:

IDSource
4020116 VUID
N0000179729 NUI
D00848 KEGG_DRUG
18609-21-7 SECONDARY_CAS_RN
6700-34-1 SECONDARY_CAS_RN
102490 RXNORM
4018051 VANDF
4018052 VANDF
4020116 VANDF
C0011816 UMLSCUI
CHEBI:4470 CHEBI
4NQ PDB_CHEM_ID
CHEMBL52440 ChEMBL_ID
CHEMBL1256818 ChEMBL_ID
DB00514 DRUGBANK_ID
D003915 MESH_DESCRIPTOR_UI
5360696 PUBCHEM_CID
6953 IUPHAR_LIGAND_ID
166 INN_ID
7487-74-3 SECONDARY_CAS_RN
7355X3ROTS UNII
18766 MMSL
44093 MMSL
4565 MMSL
4566 MMSL
73044 MMSL
d00207 MMSL
001653 NDDF
004427 NDDF
005215 NDDF
2016004 SNOMEDCT_US
387114001 SNOMEDCT_US
387237004 SNOMEDCT_US
CHEMBL1201461 ChEMBL_ID
7355X3ROTS INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Robitussin Maximum Strength Severe Multi-Symptom Cough Cold Flu HUMAN OTC DRUG LABEL 3 0031-0100 LIQUID 20 mg ORAL OTC Monograph Drug 16 sections
Robitussin Elderberry Maximum Strength Cough plus Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-2097 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
Childrens Robitussin Elderberry Cough and Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-2098 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
Robitussin Tos Seca HUMAN OTC DRUG LABEL 1 0031-8652 SYRUP 10 mg ORAL Export only 1 sections
Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8655 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Robitussin CF HUMAN OTC DRUG LABEL 3 0031-8678 LIQUID 10 mg ORAL Export only 15 sections
Childrens Robitussin Nighttime Cough Long-Acting DM HUMAN OTC DRUG LABEL 2 0031-8692 SOLUTION 15 mg ORAL OTC Monograph Drug 17 sections
CHILDRENS ROBITUSSIN COUGH AND COLD LONG-ACTING HUMAN OTC DRUG LABEL 2 0031-8693 LIQUID 15 mg ORAL OTC Monograph Drug 17 sections
Childrens Robitussin Cough Long-Acting HUMAN OTC DRUG LABEL 1 0031-8694 LIQUID 7.50 mg ORAL OTC Monograph Drug 14 sections
Childrens Robitussin Cough and Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-8702 LIQUID 20 mg ORAL OTC Monograph Drug 15 sections
Childrens Robitussin Cough and Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-8715 LIQUID 5 mg ORAL OTC Monograph Drug 15 sections
Childrens Robitussin Cough and Cold CF HUMAN OTC DRUG LABEL 3 0031-8716 LIQUID 5 mg ORAL OTC Monograph Drug 17 sections
Robitussin Maximum Strength Nighttime Cough DM HUMAN OTC DRUG LABEL 2 0031-8718 SOLUTION 30 mg ORAL OTC Monograph Drug 17 sections
Robitussin Maximum Strength Nighttime Cough DM HUMAN OTC DRUG LABEL 2 0031-8718 SOLUTION 30 mg ORAL OTC Monograph Drug 17 sections
Robitussin Maximum Strength Cough Plus Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-8719 CAPSULE, LIQUID FILLED 10 mg ORAL OTC Monograph Drug 15 sections
Childrens Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8725 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Childrens Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8726 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM HUMAN OTC DRUG LABEL 2 0031-8739 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM HUMAN OTC DRUG LABEL 2 0031-8739 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
Robitussin Peak Cold Multi-Symptom Cold HUMAN OTC DRUG LABEL 3 0031-8742 LIQUID 10 mg ORAL OTC Monograph Drug 17 sections
ROBITUSSIN LONG-ACTING COUGHGELS HUMAN OTC DRUG LABEL 1 0031-8743 CAPSULE, LIQUID FILLED 15 mg ORAL OTC Monograph Drug 15 sections
Robitussin Maximum Strength Severe Multi-Symptom 7 in 1 Relief Nighttime HUMAN OTC DRUG LABEL 3 0031-8744 CAPSULE, LIQUID FILLED 15 mg ORAL OTC Monograph Drug 17 sections
Robitussin Maximum Strength Severe Cough Plus Sore Throat HUMAN OTC DRUG LABEL 2 0031-8750 LIQUID 20 mg ORAL OTC Monograph Drug 17 sections
Robitussin Severe Multi-Symptom Cough Cold Flu HUMAN OTC DRUG LABEL 4 0031-8751 LIQUID 20 mg ORAL OTC Monograph Drug 17 sections
Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8753 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8754 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Robitussin 12 Hour Cough Relief HUMAN OTC DRUG LABEL 1 0031-8755 SUSPENSION, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Robitussin Honey Maximum Strength Cough and Chest Congestion DM HUMAN OTC DRUG LABEL 2 0031-8756 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
ROBITUSSIN COUGH PLUS CHEST CONGESTION DM HUMAN OTC DRUG LABEL 2 0031-8757 SOLUTION 20 mg ORAL OTC Monograph Drug 15 sections
Robitussin Honey Maximum Strength Nighttime Cough DM HUMAN OTC DRUG LABEL 2 0031-8758 SOLUTION 30 mg ORAL OTC Monograph Drug 17 sections